WO1997046590A1 - Materials and methods for the immobilization of bioactive species onto polymeric substrates - Google Patents
Materials and methods for the immobilization of bioactive species onto polymeric substrates Download PDFInfo
- Publication number
- WO1997046590A1 WO1997046590A1 PCT/US1997/009634 US9709634W WO9746590A1 WO 1997046590 A1 WO1997046590 A1 WO 1997046590A1 US 9709634 W US9709634 W US 9709634W WO 9746590 A1 WO9746590 A1 WO 9746590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- porous
- layer
- support member
- cross
- bioactive species
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/084—Polymers containing vinyl alcohol units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249955—Void-containing component partially impregnated with adjacent component
- Y10T428/249958—Void-containing component is synthetic resin or natural rubbers
Definitions
- the present invention relates generally to immobilized chemically functional entities. More particularly, the invention relates to materials and methods for the immobilization of bioactive species onto polymeric substrates.
- bioactive species are often immobilized onto a support member to more effectively utilize the bioactive species.
- immobilize and its derivatives, as used herein refers to the attachment of a bioactive species directly to a support member or to a support member through at least one intermediate component.
- attach and its derivatives refer to adsorption, such as, physisorption or chemisorption, ligand/receptor interaction, covalent bonding, hydrogen bonding, or ionic bonding of a polymeric substance or a bioactive species to a support member.
- Bioactive species include enzymes, organic catalysts, ribozymes, organometallics, proteins, glycoproteins, peptides, polyamino acids, antibodies, nucleic acids, steroidal molecules, antibiotics, antimycotics, cytokines, carbohydrates, oleophobics, lipids, pharmaceuticals, and therapeutics, for example.
- Cells such as, mammalian cells, reptilian cells, amphibian cells, avian cells, insect cells, planktonic cells, cells from non-mammalian marine vertebrates and invertebrates, plant cells, microbial cells, protists, genetically engineered cells, and organelles, such as mitochondria, are also bioactive species.
- non-cellular biological entities such as viruses, virenos, and prions are considered bioactive species.
- materials suitable for use as a support member for immobilizing bioactive species include hydrocarbon polymers, fluorocarbon polymers, ceramics, and metals.
- polytetrafluoroethylene and porous polytetrafluoroethylene are of particular interest as support members.
- Polytetrafluoroethylene (PTFE) is a hydrophobic fluorocarbon polymer well known to have exceptional resistance to solvent and chemical attack.
- Porous polytetrafluoroethylene can be made in a variety of ways.
- Expanded polytetrafluoroethylene (ePTFE) or stretched polytetrafluoroethylene are porous fluorocarbon polymer materials characterized primarily by a multiplicity of interconnecting voids defined by nodes and fibrils of polytetrafluorethylene material. Expanded PTFE materials, including ePTFE membranes and films described hereinbelow, may be made according to the teachings of U.S.
- porous PTFE materials are chemically stable and very biocompatible.
- the materials have easily controlled pore sizes with large surface area/volume ratios, good mechanical strength, and good resistance to fouling, among other properties. Accordingly, these materials are attractive as support members for the immobilization of bioactive species.
- hydrocarbon polymers and fluorocarbon polymers such as PTFE or porous PTFE
- PTFE or porous PTFE reactive compositions on the hydrocarbon or fluorocarbon backbone that have an undeterminable surface density, chemical identity, and chemical stability
- modification of the hydrocarbon or perfluorocarbon backbone may be spatially uneven, with microscopic or macroscopic areas of the polymer remaining unmodified.
- these surface compositions can only be empirically determined and so may be only partially known.
- modification of the backbone may be limited to the outer layers of the porous material, with the inner pore structures remaining mostly or completely unmodified.
- the unmodified regions of the polymer support member remain hydrophobic and so do not readily support wetting with high surface tension fluids.
- continuous passage of high surface tension fluids through the support member for mass transport of reactants or nutrients to and from an immobilized bioactive species cannot be established or maintained.
- Intermittent or incomplete passage of high surface tension fluid phases in a porous polymer support member can lead to channeling of the high surface tension fluid through only portions of the porous material, resulting in reduced efficiency.
- these unmodified areas cannot be immobilized with bioactive species, resulting in inefficient use of the high surface area of the porous material.
- bioactive species is immobilized onto the surfaces of a fluorocarbon polymer via simple physicochemical adsorption.
- a bioactive species is immobilized onto the surfaces of a fluorocarbon polymer via simple physicochemical adsorption.
- M. Rucha, B. Turkiewicz, and J.S. Zuk "Polymeric membranes for lipase immobilization," J. Am. Oil Chem. Soc. 67: 887 (1990) and Shults, M. et al., “ Continuous In Vivo Glucose Analysis Based On Immobilized Enzyme Bound To Derivatized Teflon Membrane," Trans. ASAIO.
- bioactive species such as cells have been immobilized to porous PTFE support members.
- bacteria and yeast cells have been immobilized in PTFE fibril matrices using an emulsion of PTFE and surfactants (F.W. Hyde, G.R. Hunt, and L.A. Errede, "Immobilization of bacteria and Saccharomyces cerevisiae in poly(tetrafluoroethylene) membranes," Appl. Environ. Microbial.. 57: 219 ( 1991 ))
- the surfactant is necessary to ensure for the presence of a continuous water phase throughout the emulsion in order to allow diffusion of nutrients to cells immobilized within the porous regions of the material.
- This method for immobilization of cells in the porous matrices of a fluorocarbon polymer is quite harsh, however, as many surfactants are cytotoxic. As a result, this method is not generally applicable to all cell types because the reaction conditions are often toxic to cell types such as plant or mammalian cells.
- the surfactant may initially obstruct some or all of the void space of the pores in such a porous support member.
- the surfactant may leach from the support member with time. This often presents a toxic environment to the immobilized cells or channelling of nutrients, resulting in a heterogeneous distribution of cells within the porous support member. Accordingly, this is often an unsuitable method for the immobilization of bioactive species.
- mammalian cells have been immobilized within ePTFE support members by forcing the cells into the pores of the material by hydrostatic pressure (University of Washington, PCT US95/03735).
- hydrostatic pressure Universal of Washington, PCT US95/03735.
- cell viability is often low due to mechanical shearing forces produced during the process.
- the ePTFE remains hydrophobic and mass transport of liquid water across the thickness of the material may remain low, resulting in suboptimal transport of nutrients to the immobilized cells.
- the hydrophobicity of the surfaces of such polymer support members can be modified with hydrophilic surface active agents, or surfactants.
- Hydrophobic surfaces are low energy surfaces that are readily wetted by low surface tension fluids, such as low molecular weight hydrocarbons or alcohols, and most low molecular weight organic solvents, such as benzene, acetone, toluene, and dioxane, etc.
- Hydrophilic surfaces are high energy surfaces that are readily wetted by high surface tension fluids. Examples of high surface tension fluids include, but are not limited to, liquid water, aqueous salt and protein solutions, dimethyl formamide, dimethyl sulfoxide, glycerol, hexamethyl phosphorictriamide, formamide, and glycol, for example.
- the presence of a surfactant provided for a surface having a hydrophilicity that initially enhanced the immobilization of bioactive species is usually unstable over time, however.
- the physicochemical stability of the immobilized bioactive species is another concern when bioactive species are immobilized with surfactants.
- the adsorption of surfactants to a polymeric support member can serve to enhance the strength of biospecies adsorption, but the biospecies may desorb from the surfactant-treated surface nevertheless.
- U.S. Patent No. 4,885,250 issued to d'Eveleigh, teaches modifying biological ligands themselves with surfactants prior to physisorption of the surfactant onto the support member.
- modification of bioactive species with surfactants prior to physisorption onto hydrophobic polymer surfaces may dramatically impact the bioactivity of the bioactive species.
- the enzyme lactate dehydrogenase was admixed with surfactants and physisorbe ⁇ onto PTFE microparticles resulting in a drop in enzymatic activity of 96% ( N.D. Danielson, and R.W. Siergiej, "Immobilization of enzymes on polytetrafluoroethylene particles packed in HPLC columns," Biotech. Bioeng.. 23: 1913 (1981)).
- the enzyme urease was modified with perfluoroalkyl chains and then physisorbed onto ePTFE resulting in an initial drop in enzymatic activity of 10 -18% and poor overall enzymatic stability (R.K. Kobos, J.W. Eveleigh, M.L.
- bioactive species may remain molecularly motile and may migrate and cluster on the surface of a hydrocarbon polymer or fluorocarbon polymer support member. This effect may be accelerated with the application of cosolvents, changes in pH, or elevated temperatures, such as autoclaving, often leading to significant reorganization of the bioactive species on the surface of the support member. This can cause a loss in wetting potential of the support member with high surface tension liquids and/or uneven spatial immobilization of a bioactive species (U.S.
- Patent No. 5,352,511 issued to Abaysekara et al.).
- modification of a bioactive species with a surfactant prior to immobilizing the bioactive species to a hydrophobic support member is most often an unsuitable method.
- Surfactants whether physisorbed onto a hydrophobic support member or attached to a bioactive species and then adsorbed to a hydrophobic support member, are subject to desorption.
- R.I. Foster, et al. in "Analysis of Urokinase Immobilization on the pnlytetrafluoroethylene vascular prosthesis.” Am. J. Surg..
- the stability of surfactant adsorption on a hydrocarbon or fluorocarbon polymer surface can be enhanced by increasing the molecular weight of the surfactant (J.H. Lee, J. Kopecek, J.D. Andrade, "Protein-Resistant Surfaces Prepared by PEO-Containing Block Copolymer Surfactants," J. Biomed. Mater. Res.. 23: 351 (1989)) or by lowering the molecular entropy of the surfactant (J.H. Lee, P. Kopeckova, J. Kopecek, J.D.
- planar molecules are of very high molecular weight and have greatly reduced molecular entropy.
- This type of cross-linking dramatically reduces the incidence of desorption or surface migration of the surfactant.
- U.S. Patent Nos. 4,929,666, issued to Schmidt et al., and 5,006,624, issued to Schmidt et al. teach adsorbing copolymers of fluoroalkyl acrylates and carboxylic vinyls, respectively, onto fluorocarbon polymer surfaces, followed by surface cross-linking of adsorbed carboxylic moieties to produce a coating highly stable to surface reorganization or to desorption.
- a hydrophilic fluorocarbon polymer of tetrafluoroethylene-co- vinyl alcohol was adsorbed and chemically cross-linked to itself using a polyether bisoxirane cross-linker (U.S. Patent No. 5,354,587, issued to Abaysekara).
- a hydrophilic hydrocarbon polymer of polyvinyl alcohol was adsorbed and cross-linked to itself using a dialdehyde cross-linker (U.S. Patent Nos. 4,113,912 and 4,193,138, both issued to Okita). This resulted in the ePTFE surface being rendered wettable with liquid water and the adsorbed copolymer molecules being highly resistant to desorption or to surface migration.
- hydrophilic surfaces have limited or greatly reduced numbers of chemically functional groups to which additional polymers or bioactive species can be attached. If the adsorbed copolymer layer is deficient in the desired number or identity of chemically functional groups it possesses, then the capacity of the adsorbed copolymer or surfactant layer to immobilize bioactive species will always remain suboptimal. Accordingly, this type of cross ⁇ linking of adsorbed surfactant or copolymer molecules on hydrocarbon or fluorocarbon polymer support members is often unsuitable for the subsequent immobilization of bioactive species.
- a support member having chemically stable and chemically variable hydrophilic polymeric surfaces attached thereto as a substrate upon which bioactive species are stably and efficiently immobilized would be useful. Such a construction would enable a practitioner to increase the number and/or variety of immobilized bioactive species. A practitioner would also be able to select a conjugation scheme for immobilization of a bioactive species that is best suited for the particular bioactive species.
- the present invention resolves the above-described problems with a construction that eliminates chemical modifications of the support member, as well as, the necessity to take preventative measures to reduce the desorption of immobilized bioactive species from the support member and the necessity to modify the bioactive species with surfactants prior to immobilization.
- the present invention p ovides a support member with hydrophilic surfaces to which bioactive species are readily immobilized.
- the hydrophilic surfaces of the construction are chemically stable. The number and type of chemically functional groups of the hydrophilic surfaces can be varied.
- the ability to vary the chemically functional groups of the hydrophilic surfaces permits a practitioner to increase the number and or variety of chemically functional groups to which bioactive species can be immobilized.
- the present invention also permits a practitioner to select a conjugation scheme for immobilization of bioactive species that best preserves the bioactivity and stability of the immobilized bioactive species.
- adsorption of a polymeric surfactant onto a support member, followed by cross-linking chains of the surfactant polymers together in situ provides a physically and chemically stable substrate, or first layer, to which a hydrophilic polymer is subsequently attached forming a second layer thereon.
- the hydrophilic polymer of the second layer is covalently attached to the cross-linked polymeric surfactant of the first layer.
- the hydrophilic polymer of the attached second layer has chemically functional groups through which bioactive species are immobilized.
- the hydrophilic polymer of the second layer is selected to provide one or more specific type of chemically functional group for immobilization of bioactive species.
- a support member having hydrophilic surfaces that are physically stable and chemically variable to which bioactive species are stably immobilized (See Figure 1).
- a plurality of layers of hydrophilic polymers may be attached to the first layer and bioactive species attached to at least one of the layers (See Figure 2).
- additional layers of hydrophilic polymers can serve to enhance the hydrophilic properties of the construction and or as a permeable protective covering for the bioactive species.
- bioactive species can be immobilized directly to chemically functional groups of the first layer, as illustrated in Figure 3, or to excess chemically functional groups of the cross-linking agent attached to the first layer, as illustrated in Figure 4.
- one embodiment of the present invention is directed to a material having immobilized bioactive species comprising a support member (12); a first layer (14) comprised of at least one species of a polymeric surfactant attached to the support member and cross-linked together in situ; a second layer (18) comprised of at least one species of a hydrophilic polymer attached to the first layer; and at least one type of bioactive species (19) attached to the second layer.
- the present invention has wide applications, it is particularly suitable for immobilization of insulin secreting pancreatic islet cells or genetically engineered insulin secreting cells. Immobilization of such cells may be useful for facilitating transplantation and/or implantation of the cells into a recipient as a means for treating or ameliorating various diseases, such as neuro-endocrine diseases, including diabetes mellitus, neurological diseases, including Parkinson's Disease, metabolic deficiency diseases, including Hurler's Disease, for example.
- the present invention is also suitable for the immobilization of renal epithelial or interstitial cells for use in renal failure therapy. Of particular interest in this regard is the use the present invention in the form of a membrane barrier for the encapsulation of immobilized therapeutic cells.
- Another use of the present invention is for the immobilization of hepatocytes for construction of extracorporeal liver assist devices.
- bioactive species such as autologous vascular endothelial cells
- bioactive species such as autologous vascular endothelial cells
- tPA heparan sulfate
- protein S various lysine compounds
- urokinase protein C, etc.
- pro-coagulant factors such as tissue factor, von Willebrand factor, factor XIII, kininogen, thrombin, etc.
- adhesion-dependent or adhesion-independent cell lines comprising genetically engineered cells for use in genetic therapy
- adhesion-dependent or adhesion-independent cell lines for use in transplantation therapy
- pro-adhesive ligands such as the tripeptide Arg-Gly-Asp, collagens, and fibronectin, for example, in order to promote adhesion of cellular bioactive species
- anti-adhesive ligands such as dextran, albumin, and polyethylene glycol, for example, in order to reduce non-specific cellular adhesion to support members
- immobilization of bacteria or yeast cells for use in bioremediation and biotechnology
- enzymes, catalytic antibodies, or phase transfer catalysts may be employed in the present invention to perform biocatalytic reactions, such as biosensing and enzyme affinity chromatography.
- proteins, peptides, carbohydrates, antibodies, lectins, or lipids may be utilized in the present invention to prepare ligand affinity or immunomatrix chromatography columns for detection or separation of products from a liquid stream.
- Another use of the present invention is as a solid substrate upon which the synthesis of peptides or drugs can be conducted.
- the present invention comprises a permeable, or semi-permeable, membrane barrier that provides a continuous solvent phase across the barrier, such as for transport of gases, nutrients, or reaction products.
- the present invention is also directed to methods for rendering the surfaces of a hydrophobic support member more hydrophilic by elevating the surface energy of these materials to support wetting and spreading of high surface tension fluids thereon.
- the present invention is also directed to methods for stably immobilizing bioactive species to the hydrophilic surfaces formed on the support member.
- Figure 1 illustrates a cross-section of the present invention (10) having a first layer (14) attached to a support member (12) wherein the letter “x" indicates that the constituents of the first layer are cross-linked together and the symbol "»" (16) indicates excess chemically functional groups of the cross-linking agent to which a second layer (18) is attached.
- the letter "B” (19) in Figure 1 represents a bioactive species.
- Figure 2 illustrates a cross-section of the present invention (20) having an additional layer (26) of hydrophilic polymers attached to a second layer (24) with bioactive species (28) immobilized to the additional layer (26).
- the letter “x” indicates that the constituents of the first layer (22) are cross-linked together and the symbol “ ⁇ ” (23) indicates excess chemically functional groups of the cross-linking agent to which a second layer (24) is attached.
- the additional layer of hydrophilic polymers is represented as being attached to the second layer by a plurality of vertical lines.
- the letter “B” (28) in Figure 2 represents a bioactive species.
- Figure 3 illustrates a cross-section of the present invention (30) having a first layer (34) attached to a support member (32) wherein bioactive species are immobilized directly to chemically functional groups of the first layer.
- the letter “x” indicates that the constituents of the first layer are cross-linked together.
- the letter “B” in Figure 3 represents a bioactive species (36).
- Figure 4 illustrate a cross-section of the present invention (40) having a first layer (44) attached to a support member (42) wherein bioactive species (48) are immobilized to the first layer through excess chemically functional groups of the cross-linking agent.
- the letter “x” indicates that the constituents of the first layer are cross-linked together.
- the symbol “ ⁇ ” (46) represents excess chemically functional groups of the cross-linking agent.
- the letter “B” (48) in Figure 4 represents a bioactive species (48).
- Figure 5 is a scanning electron micrograph of the microstructure of a porous polytetrafluoroethlyene support member having a bioactive species immobilized thereon.
- Figure 6 illustrates a cross-section of the present invention (60) having a first layer (64) attached to a support member (62) wherein the constituents of the first layer are cross-linked together and excess chemically functional groups of the cross-linking agent are present.
- the letter “x” indicates that the constituents of the first layer are cross-linked together.
- the symbol “ ⁇ ” (66) represents excess chemically functional groups of the cross-linking agent.
- Figure 7 illustrates a cross-section of the present invention (70) wherein a first layer (74) is attached to a support member (72) such that the number of chemically functional groups available for immobilizing bioactive species (71) from the first layer is increased by the addition of a second layer (78).
- the letter “x” indicates that the constituents of the first layer are cross- linked together.
- the symbol “a” (76) represents excess chemically functional groups of the cross-linking agent.
- the symbol "-A" in the region depicting the first layer indicates chemically functional groups of the constituents of the first layer that have been consumed during the formation of the first layer and are no longer available for immobilization of bioactive species.
- the letter “A” on the second layer represents unreacted chemically functional groups of the constituents of the second layer that are available for immobilization of bioactive species or attachment of additional layers of hydrophilic materials thereto.
- the letter “B” (71) in Figure 7 represents a bioactive species.
- Figure 8 illustrates a cross-section of the present invention (80) having a first layer (84) attached to a support member (82) and a second layer (86) attached to the first layer wherein a variety of chemically functional groups is provided by the second layer.
- the chemically functional groups of the first layer are represented by the letter "A.”
- Chemically functional groups of the second layer may be the same as the chemically functional groups of the first layer or the groups may be different.
- the chemically functional groups of the second layer are represented by the letter "Z.”
- the letter "B” in Figure 8 represents a bioactive species.
- Figure 9 illustrates a cell encapsulation device using a membrane constructed according to the present invention.
- Figure 10 is a photograph of an embodiment of the present invention wherein a bioactive species is immobilized in a pattern on porous polytetrafluoroethylene.
- Figure 11 illustrates a cross-section of the present invention (110) having a first layer (114) attached to a support member (112) and a second layer (116) attached to the first layer wherein a spacer compound (118) is interposed between the second layer and a bioactive species.
- the letter “x” indicates that the constituents of the first layer are cross-linked together.
- the symbol “ ⁇ ” (1 15) represents excess chemically functional groups of the cross-linking agent.
- the letter “B” (1 19) in Figure 11 represents a bioactive species.
- Figure 12 illustrates an embodiment of the present invention in the form of a vascular graft.
- the present invention is directed to polymeric materials, referred to herein as support members, having a substrate attached thereto comprised of layers of chemically stable and chemically variable hydrophilic polymers to which bioactive species are stably immobilized.
- support members having a substrate attached thereto comprised of layers of chemically stable and chemically variable hydrophilic polymers to which bioactive species are stably immobilized.
- metallic or ceramic materials can be used in the present invention as support members.
- the present invention also permits bioactive species to be readily immobilized on the surfaces defining the porous regions of the support member without significantly reducing the porosity of the support member (See Figure 5, for example).
- the result is a support member having surfaces rendered hydrophilic and wettable with high surface tension fluids throughout its bulk to which at least one type of bioactive species is immobilized.
- the construction is assembled from the following components: a support member comprised of a polymeric material; a first layer comprised of at least one species of a polymeric surfactant, or a multifunctional copolymer, comprised of at least one domain that has a physicochemical affinity for the support member to allow physicochemical adsorption of the polymer onto the surface of the support member and at least one other domain that is chemically reactive to allow covalent cross-linking with a suitable cross-linking agent; a suitable cross-linking agent; a second layer comprised of one or more hydrophilic surfactants, homopolymers, or copolymers that contain chemically functional groups capable of reacting with unconsumed free cross-linking groups from the first layer and have additional groups to provide increased hydrophilicity to the construction and for subsequent attachment of bioactive species thereto; and a bioactive species attached to the chemically functional groups of the second layer.
- Suitable materials for a hydrophobic polymeric support member include, but are not limited to, polytetrafluoroethylene, expanded polytetrafluoroethylene, porous polytetrafluoroethylene, fluorinated ethylene propylene, hexafluroropropylene, polyethylene, polypropylene, nylon, polyethyleneterephthalate, polyurethane, silicone rubber, polystyrene, polysulfone, polyester, polyhydroxyacids, polycarbonate, polyimide, polyamide, polyamino acids, regenerated cellulose, or proteins, such as silk, wool, and leather.
- Expanded, or porous, polytetrafluoroethylene (ePTFE) is particularly preferred.
- porous polytetrafluoroethylene materials are described in U.S. Patent 3,953,566 and 4,187,390, both issued to Gore, each of which is incorporated herein by reference.
- Suitable materials for hydrophilic support members include, but are not limited to, cellulosics, agarose, alginate, polyhydroxyethylmethacrylate, polyvinyl pyrrolidone, polyvinyl alcohol, polyallyamine, polyallylalcohol, polyacrylamide, and poly acrylic acid, for example.
- Suitable metals and ceramics may be suitable materials for use as support members in the present invention.
- Suitable metals for support members include, but are not limited to, titanium, stainless steel, gold, silver, rhodium, zinc, platinum, rubidium, and copper, for example.
- Suitable materials for ceramic support members include, but are not limited to, silicone oxides, aluminum oxides, alumina, silica, hydroxy apapitites, glasses, calcium oxides, polysilanols, and phosphorous oxide, for example.
- a first layer is formed on a support member by adsorbing a polymeric surfactant to the surfaces of the support member followed by cross- linking the surfactant to itself in situ.
- the first layer is optionally adsorbed to material defining the porous void spaces of the support member as well.
- a solution comprised of a polymeric surfactant dissolved in a suitable solvent at a concentration of about 0.001 % to about 99.9%, preferably about 0.25% to about 5%, is initially adsorbed onto the surfaces and optionally into the porous spaces of a porous support member simply by dipping the support member in the solution for about 0.05 minutes to about 20 minutes, to permit physisorption of the surfactant to the surfaces of the support member.
- Suitable materials for the first layer include, but are not limited to, polyvinyl alcohol, polyethylene glycol, polypropylene glycol, dextran, agarose, alginate, polyacrylamide, polyglycidol, poly(vinyl alcohol-co-ethylene), poly(ethyleneglycol-co-propyleneglycol), po!y(vinyl acetate-co-vinyl alcohol), poly(tetrafluoroethylene-co-vinyl alcohol), poly(acrylonitrile-co-acrylamide) ) poly(acrylonitrile-co-acrylic acid-co-acrylamidine), polyacrylic acid, poly-lysine, polyethyleneimine, polyvinyl pyrrolidone, polyhydroxyethylmethacrylate, and polysulfone, and their copolymers, either alone or in combination.
- Preferred copolymers for formation of the first layer are copolymers comprised of at least one moiety capable of physicochemically adsorbing to the support member, a moiety capable of chemical modification with a suitable agent, and a moiety capable of interacting with high surface tension fluids. These moieties may be selected such that one moiety fulfills all of these three roles simultaneously, fulfills two roles, or fulfills only one role.
- Suitable solvents for this purpose include, but are not limited to, methanol, ethanol, isopropanol, tetrahydrofuran, trifluoroacetic acid, acetone, water, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, benzene, hexane, chloroform, and supercritical carbon dioxide.
- the hydrophobic support member When using a hydrophobic support member and the polymer chosen for the first layer dissolves in only high surface tension solvents, the hydrophobic support member should be prewetted with a miscible solvent having a low surface tension to effect adsorption of the polymer for the first layer.
- excess adsorbed surfactant may be rinsed from the surface of the support member using fresh solvent to prevent bulk deposited surfactant from partially blocking pores of the support member. Though optional, this step is preferred in order to ensure that the pores of a porous support material, such as ePTFE, are not obstructed with surfactant.
- the polymeric surfactant of the first layer is covalently cross-linked to itself in situ using a suitable cross-linking agent to produce surface-bound planar molecules of extremely high molecular weight. These very high molecular weight molecules serve to greatly reduce or eliminate the potential for desorption or migration of the surfactant.
- Suitable reagents for use in cross-linking the polymeric surfactant in situ are compounds comprised of at least two chemically functional groups, either homofunctional or heterofunctional, that include, but are not limited to, aldehydes, epoxides, acyl halides, alkyl halides, isocyanates, amines, anhydrides, acids, alcohols, haloacetals, aryl carbonates, thiols, esters, imides, vinyls, azides, nitros, peroxides, sulfones, and maleimides, dissolved in solvents that wet the adsorbed layer.
- aldehydes aldehydes, epoxides, acyl halides, alkyl halides, isocyanates, amines, anhydrides, acids, alcohols, haloacetals, aryl carbonates, thiols, esters, imides, vinyls, azides, nitros, peroxides,
- Solvents suitable for dissolving the cross-linking reagent include, but are not limited to, acetone, water, alcohols, tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), benzene, acetonitrile, and dioxane.
- Other reagents include, but are not limited to, free radicals, anions, cations, plasma irradiation, electron irradiation, and photon irradiation.
- One preferred cross-linking agent is glutaraldehyde, preferably using a catalyst of HCl, preferably dissolved in water.
- cross-linking agent is preferably added in excess, i.e, in such an amount that sufficient unreacted chemically functional groups of the cross-linking reagent will be present to serve as points of attachment for the second layer following the cross-linking step (See Figure 6).
- the cross-linking scheme fulfills two roles. In one role, cross-linking forms surface-bound planar molecules of extremely high molecular weight. In another role, cross-linking provides chemically functional groups to which the second layer is subsequently attached. Bioactive species are then attached to unreacted chemically functional groups of the cross-linking agent (See Figure 4).
- the polymeric surfactant of the first layer can be attached to the support member with methods that do not use a chemical cross-linking agent.
- polymeric surfactants containing numerous nitrile groups can spontaneously self assemble into a stable conformal coating when adsorbed onto the support member.
- the stability of the coating is derived from the physical cross-linking of neighboring polymer chains via cyano polar interactions.
- the polymeric surfactant may be physically cross-linked using a suitable agent via acid-base coacervation, e.g., a first layer formed of a cationic polymeric surfactant can be physically cross-linked by the application of an anionic agent.
- an amphoteric polymeric surfactant may spontaneously self assemble into a conformal coating via internal acid-base coacervation.
- Minnesota Mining and Manufacturing Company in PCT/US91/07686, teach the application of a hydrophilic polyvinyl alcohol layer that is non-covalently cross-linked via inter- and intrachain polymer crystallization.
- the degree of cross-linking of the first layer may be assessed by Fourier Transform Infrared Spectroscopy (FTIR).
- FTIR Fourier Transform Infrared Spectroscopy
- the free hydroxyl groups of polyvinyl alcohol (PVA) are detectable before cross-linking at approximately 3349 cm 1 .
- the peak shifts to approximately 3383 cm 1 and decreases in height.
- an FTIR peak at approximately 2942 cm 1 due to the CH 2 groups does not change position or height as a result of cross-linking.
- a shift in the hydroxyl group (OH) peak position from approximately 3349 cm 1 to approximately 3383 cm 1 with a decrease in peak height is an indication of the amount of PVA that has become cross-linking in the formation of the first layer.
- the extent to which free, or excess, aldehyde groups of a cross-linking agent, such as glutaraldehyde, are present in the first layer following the cross-linking step can also be detected using FTIR.
- FTIR FTIR peaks at about 1590 cm 1 and about 1690 cm 1 . These peaks are believed to represent excess aldehyde groups of the first layer and its partial hydrolysis products by the exposure to steam.
- a similar article having a first layer that is briefly exposed to a glutaraldehyde cross ⁇ linking agent does not usually have an FTIR peak at 1590 cm-i. Accordingly, the degree to which a first layer contains excess chemically functional groups can be assessed by comparing the ratio of an FTIR peak at about 1690 cm 1 to an FTIR peak at about 1590 cm->.
- FTIR can also be used to detect the presence of a second layer attached to a first layer cross-linked with glutaraldehyde.
- an article of the present invention having a second layer of PVA attached to a first layer of PVA will have strong FTLR peaks at about 2950 cm 1 and t about 3350 cm 1 . These peaks represent signal from the hydrocarbon backbone and the free hydroxyl groups of the PVA, respectively, from both the first and second layers.
- the absence of an FTIR peak at about 1590 env 1 and about 1690 cm 1 indicates that substantially all of the aldehyde groups of the glutaraldehyde cross-linking agent were consumed during attachment of the second layer to the excess aldehyde groups of the first layer.
- a first or second layer of poly(lysine) on a support member may be detected by X-ray photoelectron spectroscopy (XPS).
- XPS X-ray photoelectron spectroscopy
- the addition of amino groups (NH 2 ) onto the surface can be detected by the measurement of nitrogen. Nitrogen is usually not present in either hydrocarbon or fluorocarbon support members of the present invention.
- the immobilization of cell adhesion peptides, such as the Arg-Gly-Asp amino acid sequence, onto a first or second layer of PVA for example, can be detected by XPS.
- a hydrophilic layer attached directly to a support member, or forming a first or second layer is preferably detected by elemental analysis.
- the composition of the second layer is chosen both for the ability of the second layer to cooperate with the first layer to promote wetting of the hydrophobic support member with high surface tension fluids and for its ability to provide a number and variety of chemically functional groups not usually present on the first layer to which bioactive species can be immobilized.
- various hydrophilic polymers may be selected for use in making the layer. Different hydrophilic polymers provide a variety of chemically functional groups to select from when attaching bioactive species to the second layer (See Figure 7). As a result, the second layer dictates the type of chemically functional groups to which bioactive species are immobilized.
- attachment of a second layer onto the unconsumed moieties of the cross-linking agent amplifies the number of chemically functional groups available for the immobilization of bioactive species to numbers much greater than possible using only the first layer of material on the support member. This is a key feature of the present invention because the ability to select the type and the number of chemically functional groups used to immobilize bioactive species provided by the second layer is not readily obtained with the first layer alone.
- a second layer is formed on the first layer by attaching a hydrophilic polymer to the cross-linked polymeric surfactant of the first layer through the unreacted chemically functional groups of the cross-linking reagent (See Figure 1).
- the hydrophilic polymers are covalently attached to the polymeric surfactants.
- the second layer is attached to the first layer by immersing a support member having an adsorbed and cross-linked first layer in a solution of a hydrophilic polymer of the second layer at a concentration of about 0.001 % to about 99.9%, preferably about 0.1% to about 50%, more preferably about 1.0% to about 25%, and most preferably about 0.25% to about 5%.
- the solution of hydrophilic polymer includes an appropriate catalyst, such as organic acids or bases, mineral acids or bases, Lewis acids or bases, organometallic catalysts, organic and or inorganic salts, heat, pressure, electron irradiation, photon irradiation, plasma irradiation, corona discharge, or pH, to effect attachment to the chemically functional groups of the first layer.
- an appropriate catalyst such as organic acids or bases, mineral acids or bases, Lewis acids or bases, organometallic catalysts, organic and or inorganic salts, heat, pressure, electron irradiation, photon irradiation, plasma irradiation, corona discharge, or pH, to effect attachment to the chemically functional groups of the first layer.
- Suitable hydrophilic polymers for use in forming the second layer include, but are not limited to, polyvinyl alcohol, polylysine, poly(acrylonitrile-co-acrylic acid-acrylamidine), polyacrylic acid, polyhydroxyethylmethacrylate, polyvinylpyrrolidone, polyethylene glycol, alginate, sepharose, mercaptosilane, aminosilane, hydroxylsilane, agarose, polyethyleneimine, polyallylamine, polyaminoethylmethacrylate, polyornithine, polyaminoacrylamide, polyacrylamide, polyacrolein, polyacryloxysuccinimide, polysulfone, poly (aery lonitrile-co- acrylamide), or their copolymers, either alone or in combination.
- Suitable solvents for dissolving the hydrophilic polymers include, but are not limited to, water, alcohols, dioxane, dimethylformamide, tetrahydrofuran, and acetonitrile, etc.
- the chemically functional groups of the first layer include, but are not limited to, hydroxyl groups, carboxyl groups, acid anhydride groups, acyl halide groups, alkyl halide groups, aldehyde groups, alkene groups, amide groups, amine groups, guanidine groups, malimide groups, thiol groups, sulfonate groups, sulfonyl halide groups, sulfonyl ester groups, carbodiimide groups, ester groups, cyano groups, epoxide groups, proline groups, disulfide groups, imidazole groups, imide groups, imine groups, isocyanate groups, isothiocyanate groups, nitro groups, and azide groups.
- the chemically functional groups of the first layer are depicted in Figure 8 as the letter "A.”
- the chemically functional groups of the second layer include, but are not limited to, any of the groups listed for the first layer and or hydroxyl groups, carboxyl groups, acid anhydride groups, acyl halide groups, alkyl halide groups, aldehyde groups, alkene groups, amide groups, amine groups, guanidine groups, malimide groups, thiol groups, sulfonate groups, sulfonyl halide groups, sulfonyl ester groups, carbodiimide groups, ester groups, cyano groups, epoxide groups, proline groups, disulfide groups, imidazole groups, imide groups, imine groups, isocyanate groups, isothiocyanate groups, nitro groups, and azide groups.
- the chemically functional groups of the second layer are represented in Figure 8 by the letter "Z.”
- variability in the number and identity of the functional groups of the second layer can be used to increase the wettability of the support member with high surface tension fluids.
- a porous hydrophobic support member is modified only at its surface by a thin first and second layer, leaving the material defining the porous void spaces of the support member unmodified and hydrophobic.
- the first and second layers can also be formed on the material defining the interior porous void spaces of the porous support member and bioactive species immobilized thereon.
- a continuous water phase through the pores of the support member can be readily established and maintained, resulting in good transport of reaction products or nutrients, for example, across the porous support member.
- Thin coatings are particularly preferred for porous support members because thin coatings do not appreciably decrease the porosity of the support member.
- the material's permeability to air in Gurley seconds is between about 22 seconds to about 24 seconds.
- a porous PTFE material modified according to the present invention has a permeability to air of about 24 Gurley seconds to about 26 Gurley seconds.
- the interaction of a solution-phase reactant with an immobilized bioactive species may be suboptimal.
- steric hindrances between the first or second layer and the immobilized bioactive species may limit the approach of the solution phase reactant to the bioactive species.
- physical bulk, electrostatic repulsion, or inappropriate positioning of the bioactive species may also contribute to reduced efficiency of the immobilized bioactive species. Accordingly, it may be desirable to place one or more additional compounds as a "spacer" or "tether" between the chemically functional groups of the first or second layer and the bioactive species to increase the space between the layer and the bioactive species.
- Suitable compounds for use as a spacer include, but are not limited to, succinic acid, diaminohexane, glyoxylic acid, short chain polyethylene glycol, and glycine, for example. It is understood that the second layer may itself serve as a spacer arm without necessitating the use of a separate spacer compound.
- the covalent immobilization of biospecies onto support members according to the present invention is generally non-reversible, i.e., the biospecies is not readily released from the first or second layer of the support member.
- Spacers, or tethers capable of selectively releasing an immobilized biospecies have utility in receptor/ligand interactions, molecular identification and characterization of antibody/antigen complexes, and selective purification of cell subpopulations, etc.
- a selectively cleavable spacer affords predictable and controlled release of biospecies from the support member as opposed to the unstable physisorption of biospecies discussed in the Background section above.
- Selective release of the biospecies is performed by cleaving the spacer compound under appropriate reaction conditions including, but not limited to, photon irradiation, enzymatic degradation, oxidation/reduction, or hydrolysis, for example.
- the selective cleavage and release of immobilized biospecies may be accomplished using techniques known to those skilled in the art (see for example, H.R. Horton & H.E. Swaisgood, "Covalent immobilization of proteins by techniques which permit subsequent release," Meth. Enzvmologv. 135: 130 (1987); S.S.Wong, Chemistry of Protein Conjugation and Cross-Linking, CRC Press (1991); and U.S. Patent No.
- Suitable compounds for use as cleavable tethers, or cleavable spacers include, but are not limited to, polyhydroxyacids, polyanhydrides, polyamino acids, tartarates, and cysteine-linkers such as Lomant's Reagent, for example.
- the present invention is not limited to the above-described embodiments having a first layer and a second layer.
- additional layers of hydrophilic polymers may be attached to existing layers on the support member to form constructions with multiple layers of hydrophilic material attached thereto.
- the following examples illustrate how the present invention can be made and used.
- This example illustrates a method for forming a first layer comprised of polymeric surfactants on an expanded polytetrafluoroethylene support member by adsorption and cross- linking of the polymeric surfactant on the exterior surfaces of an expanded polytetrafluoroethylene film, as well as, the surfaces delineating the porous regions of the film.
- the method is as follows.
- An ePTFE support member in the form of a film (W.L. Gore & Associates, Inc.), having a thickness of about 50 ⁇ m and a porosity as measured in Gurley seconds of about 22 to 24, was immersed in a 1.5% solution of a random copolymer of tetrafluoroethylene and vinyl alcohol (hereinafter HPL-1, Japan Gore, Inc.) in methanol (w/v) for about 5 minutes.
- HPL-1 tetrafluoroethylene and vinyl alcohol
- methanol w/v
- the adsorbed layer of HPL-1 was cross-linked in situ on the ePTFE support member by dipping the film construction in an aqueous solution of about 5% glutaraldehyde, with about 1 % HCl as catalyst, for about 5 minutes, at about 70°C to cross-link the vinyl alcohol groups of the adsorbed HPL-1 copolymer chains via acetalization.
- This film construction was rinsed in water to remove excess glutaraldehyde and HCl.
- the resulting film construction was an ePTFE support member having a first layer formed thereon.
- This example illustrates the stability of the first layer of the film construction described in Example 1.
- the stability of a particular layer is expressed in terms of the hydrophilicity of the surface of the film construction.
- a hydrophilic surface is a surface that is readily wetted with high surface tension fluids.
- a drop of water is placed on the test surface and its behavior observed. If the water drop spread on the surface of the material to wet and fill the pores of the material with water and render the material transparent, the surface of the material was considered to be hydrophilic. If the water drop did not spread on the surface of the material or wet the pores to fill them substantially completely with water, but rounded up on the surface of the material, rendering the material translucent or opaque, the surface of the material was considered to be hydrophobic.
- a first film construction was made as described in Example 1.
- a second film construction was made similarly to the film construction of Example 1, but without the cross ⁇ linking step. Both constructions were immersed in various refluxing solvents, such as water, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), and acetone, for about 24 hours. The film constructions were then removed from the solvent, rinsed in fresh solvent, and air dried. The hydrophilicity of the particular surface was then tested by applying one or more drops of deionized water to the surface. The second film construction showed a significant decrease in the hydrophilicity of the surfaces of the construction.
- various refluxing solvents such as water, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), and acetone
- Example 1 The reduced hydrophilicity was believed to be due primarily to desorption of the copolymer from the surface of the constructions and to copolymer chain migration on the surface of the constructions.
- first and second film constructions were steam autoclaved ten times at about 120°C for about 15 minutes each, air dried, and then dipped in deionized water.
- the construction was considered hydrophobic.
- the first film construction became spontaneously wetted to completion with the deionized water and so was considered hydrophilic.
- This example illustrates use of another reagent for cross-linking the polymeric surfactant of Example 1.
- the method is as follows.
- Example 4 Following adsorption of the surfactant to the surfaces of the ePTFE support member in Example 1, the film construction was dipped in an aqueous solution of about 2% polyethylene glycol dialdehyde (3400 g/mol, Shearwater Polymers), with about 0.1 % HCl as catalyst, for about 30 minutes, at about 75°C, to cross-link the vinyl alcohol groups of the adsorbed HPL-1 copolymer chains via acetalization. This film construction was rinsed in water to remove excess polyethylene glycol dialdehyde and HCl. The resulting film construction was an ePTFE support member having a first layer formed thereon.
- Example 4 Example 4
- This example illustrates use of another reagent for cross-linking the polymeric surfactant of Example 1.
- the method is adapted from U.S. Patent No. 5,354,587, issued to Abaysekara, and is performed as follows.
- the film construction was dipped in a methanolic solution of about 0.25% potassium hydroxide (KOH) for about 30 seconds followed by air drying. The film construction was then dipped in an acetone solution of about 10% polyethylene glycol diglycidyl ether (400 g/mol, Polysciences) for about 5 minutes. The film construction was cured in vacuo at about 75°C for about 3 hours to cross-link the vinyl alcohol groups of the adsorbed HPL-1 copolymer chains via epoxide alcoholysis. The film construction was rinsed in distilled water to remove excess polyethylene glycol diglycidyl ether and KOH. The resulting film construction was an ePTFE support member having a first layer formed thereon.
- KOH potassium hydroxide
- This example illustrates the stability of the first layer of the film construction described in Example 4.
- the stability of a particular layer is expressed in terms of the hydrophilicity of the surface of the film construction.
- a hydrophilic surface is a surface that is readily wetted with high surface tension fluids.
- a drop of water is placed on the test surface and its behavior observed. If the water drop spread on the surface of the material to wet and fill the pores of the material with water and render the material transparent, the surface of the material was considered to be hydrophilic. If the water drop did not spread on the surface of the material or wet the pores to fill them substantially completely with water, but rounded up on the surface and rendered the material translucent or opaque, the surface of the material was considered to be hydrophobic.
- a first film construction was made as described in Example 4.
- a second film construction was made similarly to the film construction of Example 4, but without the cross ⁇ linking step. Both constructions were immersed in various refluxing solvents, such as water, dimethyl formamide (DMF) for about 24 hours. The film constructions were then removed from the solvent, rinsed in fresh solvent, and air dried. The hydrophilicity of the particular surface was then tested by applying one or more drops of deionized water to the surface. The second film construction showed a significant decrease in the hydrophilicity of the surfaces of the film construction.
- various refluxing solvents such as water, dimethyl formamide (DMF)
- the reduced hydrophilicity was believed to be due primarily to desorption of the copolymer from the surface of the constructions and to copolymer chain migration on the surface of the constructions.
- the first film construction i.e., with cross ⁇ linking, remained hydrophilic under the same conditions.
- the first and second film constructions were steam autoclaved at about 120°C for about 20 minutes, air dried, and then dipped in deionized water.
- the film construction was considered hydrophobic.
- the first film construction became spontaneously wetted to completion with the deionized water and so was considered hydrophilic.
- This example illustrates a method for forming a first layer comprised of polymeric surfactants on an expanded polytetrafluoroethylene support member by adsorption and cross ⁇ linking of the polymeric surfactant on the exterior surfaces of an expanded polytetrafluoroethylene film, as well as, the surfaces delineating the porous regions of the film.
- the method is as follows.
- Gore & Associates, Inc. having a thickness of about 50 ⁇ m and a porosity as measured in Gurley seconds of about 22 to 24, was prewetted with isopropyl alcohol and then immersed in a solution of about 1% polyvinyl alcohol (PVA) (Sigma) in distilled water (w/v) for about 5 minutes. This film construction was then immersed in distilled water for about 10 minutes to rinse unadsorbed bulk copolymer from the ePTFE surface.
- PVA polyvinyl alcohol
- the adsorbed layer of PVA was cross-linked in situ on the ePTFE support member by dipping the film construction in an aqueous solution of about 5% glutaraldehyde, with about 1 % HCl as catalyst, for about 20 minutes, at about 25°C to cross-link the vinyl alcohol groups of the adsorbed PVA copolymer chains via acetalization.
- This film construction was rinsed in water to remove excess glutaraldehyde and HCl.
- the resulting film construction was an ePTFE support member having a first layer formed thereon.
- This example illustrates used of another reagent for cross-linking the polymeric surfactants of Example 6.
- the method is as follows.
- the film construction was dipped in an aqueous solution of about 2% -polyethylene glycol dialdehyde (3400 g/mol, Shearwater Polymers), with about 0.1 % HCl as catalyst, for about 30 minutes, at about 75°C, to cross-link the vinyl alcohol groups of the adsorbed PVA copolymer chains via acetalization.
- This film construction was rinsed in water to remove excess polyethylene glycol dialdehyde and HCl.
- the resulting film construction was an ePTFE support member having a first layer formed thereon.
- This example illustrates used of another reagent for cross-linking the polymeric surfactants of Example 6.
- the method is adapted from U.S. Patent No. 5,354,587, issued to Abaysekara, and is performed as follows.
- the film construction was dipped in a methanolic solution of about 0.25% potassium hydroxide (KOH) for about 30 seconds followed by air drying. The film construction was then dipped in an acetone solution of about 10% polyethylene glycol diglycidyl ether (400 g/mol, Polysciences) for about 5 minutes. The film construction was cured i vacuo at about 75°C for about 3 hours to cross-link the vinyl alcohol groups of the adsorbed PVA copolymer chains via epoxide alcoholysis. The film construction was rinsed in distilled water to remove excess polyethylene glycol diglycidyl ether and KOH. The resulting film construction was an ePTFE support member having a first layer formed thereon.
- KOH potassium hydroxide
- This example illustrates the formation and attachment of a second layer comprised of the hydrophilic polymer polyvinyl alcohol (PVA) on the first layer formed on the ePTFE support member described in Example 1.
- PVA hydrophilic polymer polyvinyl alcohol
- Example 1 The film construction of Example 1 was immersed in an aqueous solution of about 1.0 % polyvinyl alcohol (PVA) (Sigma), with about 1 % HCl as catalyst, at about 75°C, for about 5 minutes, to allow covalent attachment of PVA to free aldehyde groups remaining after the first layer has been cross-linked. Following attachment of the second layer to the first layer via acetal linkages, excess PVA was rinsed from the film construction by immersing the construction in water. The resulting film construction was immediately and spontaneously wettable with liquid water.
- PVA polyvinyl alcohol
- This example illustrates the formation and attachment of a second layer comprised of the hydrophilic polymer polyvinyl alcohol (PVA) on the first layer formed on the ePTFE support member described in Example 6.
- PVA hydrophilic polymer polyvinyl alcohol
- Example 6 The film construction of Example 6 was immersed in an aqueous solution of about 1.0 % polyvinyl alcohol (PVA) (Sigma), with about 1 % HCl as catalyst, at about 25°C, for about 10 minutes, to allow covalent attachment of PVA to free aldehyde groups remaining after the first layer has been cross-linked. Following attachment of the second layer to the first layer via acetal linkages, excess PVA was rinsed from the film construction by immersing the construction in water. The resulting film construction was immediately and spontaneously wettable with liquid water.
- PVA polyvinyl alcohol
- This example illustrates the formation and attachment of a second layer comprised of the hydrophilic polymer polylysine on the first layer formed on the ePTFE support member described in Example 1.
- Example 1 The film construction of Example 1 was immersed in a buffered aqueous solution of about 0.5% polylysine hydrobromide (100,000 g/mol, Sigma) at about pH 9 at about 25 °C for about 2 hours to allow covalent attachment of polylysine to free surface aldehyde groups generated during cross-linking of the first layer. Cyanoborohydride was added to reduce the imine linkage to a secondary amine. Following attachment of the second layer to the first layer via imine linkages, excess polylysine was washed by immersing the film construction in distilled water. The resulting film construction was immediately and spontaneously water wettable.
- polylysine hydrobromide 100,000 g/mol, Sigma
- This example illustrates the formation and attachment of a second layer comprised of the hydrophilic polymer polylysine on the first layer formed on the ePTFE support member described in Example 6 .
- Example 6 The film construction of Example 6 was immersed in a buffered aqueous solution of about 0.5% polylysine hydrobromide (100,000 g/mol, Sigma) at about pH 9 at about 25 °C for about 2 hours to allow covalent attachment of polylysine to free surface aldehyde groups generated during cross-linking of the first layer. Following attachment of the second layer to the first layer via imine linkages, excess polylysine was washed by immersing the film construction in distilled water. Cyanoborohydride was added to reduce the imine linkage to a secondary amine. The resulting film construction was immediately and spontaneously water wettable.
- polylysine hydrobromide 100,000 g/mol, Sigma
- Example 9 illustrates the stability of the first and second layers of the film construction described in Example 9.
- the film construction of Example 9 was extracted in dimethyl formamide (DMF) at about 120°C for about 2 days. No statistically significant decrease in the mass of the construction was observed using gravimetry, indicating no detectable desorption of the first and second layers from the surface of the support member.
- This film construction spontaneously and completely wetted with liquid water. As a result, the surface of the film construction was considered to be stably hydrophilic.
- the film construction was immersed in about 5% HCl at about 80°C for about 2 days, rinsed in water, and then air dried. Following this treatment, the film construction remained hydrophilic.
- Example 10 illustrates the stability of the first and second layers of the film construction described in Example 10.
- the film construction of Example 10 was extracted in dimethyl formamide (DMF) at about 120°C for about 1 day. No statistically significant decrease in the mass of the construction was observed using gravimetry, indicating no detectable desorption of the first and second layers from the surface of the support member.
- This film construction spontaneously and completely wetted with liquid water. As a result, the surface of the film construction was considered to be stably hydrophilic.
- the film construction was immersed in about 5% HCl at about 80°C for about 2 days, rinsed in water, and then air dried. Following this treatment, the film construction remained hydrophilic.
- Example 9 illustrates the stability of the first and second layers of the film construction described in Example 9.
- the film construction of Example 9 was extracted in distilled water at about 25 ' C for about 7 days. No statistically significant decrease in the mass of the construction was observed using gravimetry, indicating no detectable desorption of the first and second layers from the surface of the support member.
- This film construction spontaneously and completely wetted with liquid water. As a result, the surface of the film construction was considered to be stably hydrophilic.
- Example 10 illustrates the stability of the first and second layers of the film construction described in Example 10.
- the film construction of Example 10 was extracted in distilled water at about 25'C for about 7 days. No statistically significant decrease in the mass of the construction was observed using gravimetry, indicating no detectable desorption of the first and second layers from the surface of the support member.
- This film construction spontaneously and completely wetted with liquid water. As a result, the surface of the film construction was considered to be stably hydrophilic.
- This example illustrates the lack of decreased permeability of a film construction as described in Example 9.
- scanning electron micrographs were first taken of the microstructure of the film construction to view the first and second layers on the nodes and fibrils of the ePTFE support member.
- the results of these micrographs showed no visible plugging of pores or bulk deposition of surfactant therein (See Figure 5). This indicates that the adsorption and cross-linking of the first layer and attachment of the second layer was very thin.
- surfactant-treated ePTFE does not increase resistance to mass transport by plugging of pores, pore size was measured using a Coulter Porometer.
- a film construction was prepared as described in Example 9 and helically wrapped around a cylindrical mandrel to form a tube.
- the mean pore size of the film-tube construction was measured to be 0.173 ⁇ 0.006 ⁇ m, while the mean pore size of a similar untreated ePTFE tubing was measured to be 0.180 ⁇ 0.001 ⁇ m.
- an ePTFE support member having a first and second layer of the present invention does not increase resistance to mass transport by plugging of pores
- the permeability of the film construction to glucose flux was measured.
- an ePTFE film-tube construction was prepared as previously described. The glucose mass transport coefficient of the film-tube construction was measured to be 0.98 ⁇ m/sec, while the glucose mass transport coefficient of a similar untreated ePTFE tubing was measured to be 0.25 ⁇ m/sec.
- Example 10 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 10.
- the film construction of Example 10 was immersed in an acetone solution containing about 5% carbonyldiimidazole (Sigma) for about 60 minutes to convert vinyl alcohol groups to reactive imidazole carbamates.
- the film construction was rinsed in acetone, then immersed in a buffered solution of about 0.1 % Gly-Arg-Gly-Asp-Ser (Sigma) at about pH 9 for about 24 hours at about 4°C to allow conjugation of the peptide onto the imidazole carbamates.
- Excess imidazole groups were converted back to vinyl alcohol groups via hydrolysis in water at about pH 7.4 for about 24 hours.
- Example 9 also illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 9.
- the film construction of Example 9 was immersed in a dimethylformamide (DMF) solution containing about 10% hexamethylene diisocyanate (Aldrich), with about 0.5% dimethylaminopyridine as catalyst, for about 1 hour in order to place free isocyanate groups upon the PVA layer ( protocol adapted from A. Kondoh, K. Makino, T. Matsuda, "Two- Dimensional Artificial Extracellular Matrix: Bioadhesive Peptide-lmmobilized Surface Design," J. Applied Polvm. Sci.. 47: 1983 (1993)).
- DMF dimethylformamide
- Aldrich hexamethylene diisocyanate
- the film construction was then rinsed in aqueous IM KOH to hydrolyze the free isocyanates to free amines, after which it was immersed in a DMF solution containing about 0.5% disuccinimidyl suberate (Pierce) for about 1 hour to place free succinimidyl groups upon the free amines.
- the film construction was rinsed in DMF, then immersed in a buffered solution of about 0.1 % Gly-Arg-Gly-Asp-Ser (Sigma) at about pH 9 for about 12 hours to allow conjugation of the peptide onto the free succinimidyl groups.
- Example 9 also illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 9.
- the film construction of Example 9 was immersed in a solution of about 5% glyoxylic acid (Sigma), with 1 % HCl as catalyst, for about 15 minutes at about 80°C to acetalize the PVA of the second layer, thereby conjugating free carboxylic acid groups.
- the film construction was then immersed in an acetone solution of about 1 % N,N,N',N'- tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (Fluka), with about 0.25% dimethylaminopyridine as catalyst, for about 2 hours, to convert the carboxylic acids to reactive succinimidyl esters.
- the film construction was rinsed in acetone, then immersed in a buffered solution of about 0.1 % Gly-Arg-Gly-Asp-Ser (Sigma) at about pH 9 for about 24 hours to allow conjugation of the peptide onto the succinimidyl groups.
- Example 9 also illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 9.
- the film construction of Example 9 is immersed in a solution of about 5 % glyoxylic acid, with about 1% HCl as catalyst, for about 10 minutes at about 80°C to place free carboxylic acid groups upon the PVA layer.
- the film construction is immersed in an aqueous buffered solution of about 1 % l-ethyI-3-(dimethylaminopropyl) carbodiimide (EDC) (Sigma) at about pH 5 for about 1 hour at about 4°C to convert the carboxylic acids to reactive O- acylureas.
- the film construction is rinsed in the buffered solution, then immersed in the buffered solution with about 0.1 % Gly-Arg-Gly-Asp-Ser (Sigma) at about pH 9 for about 24 hours to allow conjugation of the peptide onto the O-acylureas.
- Example 18 illustrates the immobilization of a bioactive species in the form of cells to a film construction of the present invention as described in Example 18.
- the film construction of Example 18 was seeded with rat insulinoma cells in cell culture medium. These cells have receptors that assist the cells in adhering to certain substrates or ligands.
- the ligand, Gly-Arg-Gly-Asp-Ser, described in Example 18 is commonly known to bind to receptors on cells involved in adhesion of the cell to other cells, or other substrates.
- the Arg-Gly-Asp ligand was used to immobilize the rat insulinoma cells to the film construction of Example 18.
- ePTFE modified with a polyvinyl alcohol surfactant according to Example 10
- Gly-Arg- Gly-Asp-Ser tissue culture polystyrene
- tissue culture polystyrene is commonly used as a substrate for a wide variety of cells in tissue culture. The extent of cell adhesion was quantified by visualizing the cells under phase contrast microscopy 12 hours after the cell seeding.
- tissue culture polystyrene supported spreading of all seeded cells after 12 hours, as expected. Similar results were seen with the film construction of Example 18. Unmodified ePTFE and PVA-modified ePTFE made according to Example 10 supported less than 5% spread cells at 12 hours, however. These data indicate, among other things, that the immobilization of cells onto ePTFE was enhanced by immobilizing bioactive ligands for which the cells have receptors onto the ePTFE surface. The data also indicate that the presence of a first and second layer alone did not improve cell immobilization.
- the geometry is essentially cylindrical.
- An important feature of the device is a cell displacing core located in the center of the device to place cells away form the center of the device near the cell encapsulation membrane where maximum exchange of nutrients, gases, wastes, and cell products between cells encapsulated in the device and the external environment of the device can occur.
- a film construction as described in Example 10 was made and helically wrapped on a cylindrical mandrel to form a tube, or cover, about 3 cm in length, having an inner diameter of about 1.7 cm.
- a hydrogel rod, or core, about 3 cm in length, having an outer diameter of about 1.6 cm was inserted into the tube.
- the tube was sealed at one end by applying a constrictive silicone rubber cuff over the tube and the core (See Figure 8).
- the device was filled with a slurry of adhesion-independent rat insulinoma cells in cell culture medium. The remaining open end of the tube was sealed using constrictive silicone rubber cuffs to prevent passage of cells out of the tube.
- the first and second layers of the film construction of the tube caused the tube to spontaneously wet when exposed to the culture medium.
- the tube became wetted with the aqueous portion of the culture medium, the tube became transparent, allowing visualization of the cells contained therein.
- the cell encapsulation device was maintained in vitro using standard cell culture techniques. The viability of the cells was assessed by monitoring glucose metabolism. The cells remained viable and produced lactic acid via glycolysis while enclosed in the device for up to 3 weeks.
- Example 18 Many mammalian cells useful for biotechnology are adhesion dependent. For proper health of these cells, the cells must have a suitable surface upon which to adhere and spread. If the cells are not provided with a suitable surface, their metabolic output may be reduced, and in extreme circumstances cell death may occur.
- the present example illustrates that a membrane as described in Example 18 and formed into an assembly according to Example 23 may also maintain the viability of adhesion-dependent smooth muscle cells.
- Two film-tube constructions were initially made. A first construction was made as described in Example 18 having the peptide ligand Gly-Arg-Gly-Asp-Ser. A second construction similar to Example 10 was made. Each film construction was formed into a cell encapsulation device according to Example 23, following autoclaving. A hydrogel core in the form of a rod was inserted into each tubular cell encapsulation device. One end of each device was sealed with a constrictive silicone rubber cuff as described in Example 23. Each device was filled with a slurry of canine smooth muscle cells in cell culture medium. The remaining open end of each device was sealed using constrictive silicone rubber cuffs to prevent passage of cells out of the device.
- spacer arms may be provided as a tether, or linkage, to provide a physical space between the bioactive species and the second layer in order to relieve steric limitations between these two components.
- a variety of hydrophilic and hydrophobic spacer arms may be attached onto the multilayered structure using techniques known to those skilled in the art.
- the film construction of Example 9 was immersed in an aqueous solution of about 5% -polyethylene glycol dialdehyde (3400 g/mol, Shearwater Polymers), with 1 % HCl as catalyst, for about 5 minutes, at about 80°C, to place free aldehyde groups on the PVA surface tethered by a PEG chain. Bioactive species were then be immobilized onto these free aldehydes using techniques known to those skilled in the art.
- a Gly-Arg-Gly-Asp-Ser ligand was immobilized to the luminal surface of an ePTFE vascular graft (W.L. Gore & Associates, Inc., Flagstaff, AZ). Following autoclaving, the graft was seeded with canine endothelial cells. The cells were allowed to adhere for 10 days in culture. Adhesion of the endothelial cells was assessed using a stain specific for endothelial low density lipoprotein (LDL) vacuoles (Biomedical Technologies). The LDL stain showed a confluent monolayer of functional endothelial cells covering the entire treated surface of the vascular graft.
- LDL low density lipoprotein
- a vascular graft having a 6mm inner diameter made according to Example 26 was grafted in a greyhound dog as a femoral-popliteal artery by-pass for 2 hours. No anticoagulants were used in the experiment.
- the graft was removed and examined for the presence of endothelial cells immobilized on the luminal surface of the graft. Endothelial cells were observed on the luminal surface of the vascular graft following the 2 hour test. Little or no thrombus formation was observed on the luminal surface of the graft.
- adhesion-dependent cell types may require the presence of a surface bound peptide factor for immobilization.
- Cells were not immobilized onto the untreated hydrophobic ePTFE support member, but were attached to the two layer PVA system having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereon as per Example 22. Therefore, cells may be immobilized onto a support member in a pattern by placing the first layer, the second layer, and the bioactive species in specific locations on the support member. For example, a construction of Example 10 was sandwiched between two other identical membranes. A rubber stamp having a distinct pattern was wetted with isopropyl alcohol.
- the isopropyl alcohol was applied to the membrane "sandwich” to wet all the ePTFE layers with only the pattern of the stamp.
- the membrane sandwich was then treated according to the protocol of Example 18 to conjugate the peptide in the shape of the pattern on the rubber stamp.
- the central membrane was removed from the sandwich configuration and seeded with canine endothelial cells. After about 12 hours, cells were immobilized in the shape of the pattern. No cells were seen adhered to the area of the ePTFE support member where the conjugated peptide had not been immobilized.
- the immobilized canine cells remained viable, immobilized, and confined to the patterned area of the support member for at least 4 weeks. See Figure 10, for example.
- This example illustrates the present invention having a support member comprised of a polyester material.
- a film of polyester (Poretics) is first immersed in isopropanol to wet the membrane.
- the film is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min to allow adsorption of the PVA.
- PVA polyvinyl alcohol
- the film is rinsed in deionized water for about 10 min.
- the film is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ.
- the resulting film construction is a polyester support member having a first layer formed thereon.
- This example illustrates the present invention having a support member comprised of a polycarbonate material.
- a film of polycarbonate (Poretics) is first immersed in isopropanol to wet the membrane. The film is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min to allow adsorption of the PVA. Next, the film is rinsed in deionized water for about 10 min. Lastly, the film is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ. The resulting film construction is a polycarbonate support member having a first layer formed thereon.
- PVA polyvinyl alcohol
- This example illustrates the present invention having a support member comprised of a polyethylene material.
- a film of polyethylene (Whatman) is first immersed in isopropanol to wet the membrane.
- the film is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min to allow adsorption of the PVA.
- PVA polyvinyl alcohol
- the film is rinsed in deionized water for about 10 min.
- the film is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ.
- the resulting film construction is a polyethylene support member having a first layer formed thereon.
- This example illustrates the present invention having a support member comprised of a polyvinyl idenefluoride material.
- a film of polyvinylidenefluoride (Millipore) is first immersed in isopropanol to wet the membrane. The film is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min. to allow adsorption of the PVA. Next, the film is rinsed in deionized water for about 10 min. Lastly, the film is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ.
- PVA polyvinyl alcohol
- the resulting film construction is a polyvinylidenefluoride support member having a first layer formed thereon.
- This example illustrates the present invention having a support member comprised of silver metal.
- a membrane of silver metal (Poretics) is first immersed in isopropanol to wet the metal.
- the metal is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min. to allow adsorption of the PVA.
- PVA polyvinyl alcohol
- the metal is rinsed in deionized water for about 10 min.
- the metal is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ.
- the resulting film construction is a silver metal support member having a first layer formed thereon.
- This example illustrates the present invention having a support member comprised of a cellulose acetate material.
- a film of cellulose acetate (Millipore) is first immersed in isopropanol to wet the membrane. The film is then immersed in a solution of 1 % polyvinyl alcohol (PVA) (Sigma) for about 5 min. to allow adsorption of the PVA. Next, the film is rinsed in deionized water for about 10 min. Lastly, the film is immersed in a solution of about 5% glutaraldehyde and about 1 % HCl for about 20 minutes to cross-link the PVA in situ.
- PVA polyvinyl alcohol
- the resulting film construction is a cellulose acetate support member having a first layer formed thereon.
- Example 30 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 30.
- the film of Example 30 is treated additionally according to Example 10 to place a second layer thereon.
- the film is then immobilized with the bioactive peptide Gly-Arg-Gly-Asp-Ser according to Example 18.
- the resulting film construction is a polycarbonate support member having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereto.
- Example 31 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 31.
- the film of Example 31 is treated additionally according to Example 10 to place a second layer thereon.
- the film is then immobilized with the bioactive peptide Gly-Arg-Gly-Asp-Ser according to Example 18.
- the resulting film construction is a polyethylene support member having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereto.
- Example 32 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 32.
- the film of Example 32 is treated additionally according to Example 10 to place a second layer thereon.
- the film is then immobilized with the bioactive peptide Gly-Arg-Gly-Asp-Ser according to Example 18.
- the resulting film construction is a polyvinylidenefluoride support member having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereto.
- Example 33 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 33.
- the film of Example 33 is treated additionally according to Example 10 to place a second layer thereon.
- the film is then immobilized with the bioactive peptide Gly-Arg-Gly-Asp-Ser according to Example 18.
- the resulting film construction is a silver metal support member having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereto.
- Example 34 illustrates the immobilization of a bioactive species in the form of peptides to a film construction of the present invention as described in Example 34.
- the film of Example 34 is treated additionally according to Example 10 to place a second layer thereon.
- the film is then immobilized with the bioactive peptide Gly-Arg-Gly-Asp-Ser according to Example 18.
- the resulting film construction is a cellulose acetate support member having the bioactive species Gly-Arg-Gly-Asp-Ser immobilized thereto.
- Example 36 illustrates the immobilization of a bioactive species in the form of cells to a film construction of the present invention as described in Example 36.
- Cells are seeded on the membrane of Example 36 according to Example 22.
- the expected results show that the film construction of Example 36 supports the immobilization of cells, while the unmodified polypropylene films are unable to support the immobilization of cells.
- This example illustrates the present invention having a support member comprised of an expanded polytetrafluoroethylene (ePTFE) covered stent in the form of a composite.
- ePTFE expanded polytetrafluoroethylene
- a nitinol wire stent is covered with an ePTFE tube.
- the composite device is immersed in isopropyl alcohol to prewet the ePTFE. This is followed by immersion in a solution of about 1 % polyvinyl alcohol (PVA) (Sigma) in distilled water (w/v) for about 5 minutes followed by a washing in distilled water for about 10 minutes to remove unadsorbed bulk copolymer.
- PVA polyvinyl alcohol
- the adsorbed PVA is cross-linked according to that detailed in Example 6 to form a first layer on the ePTFE support member component of the stent composite.
- a second layer is then applied to the first layer using the procedure illustrated in Example 12.
- the amine groups now immobilized on the ePTFE support member are linked via aldehyde cross-linking to a desired bioactive species.
- the resulting construction is a second layer attached to the first with bioactive species immobilized thereon.
- This example describes a method for the detection of the degree of cross-linking of the PVA.
- Fourier Transform Infrared Spectroscopy is used to detect the free hydroxyl groups before and after cross-linking.
- a shift in the hydroxyl group (OH) peak position from approximately 3349 cm 1 to approximately 3383 cm-' with a decrease in peak height is proportional to the degree of cross-linking.
- This example illustrates a method for the detection of excessive cross-linking of the of a first layer comprised of polyvinyl alcohol (PVA) in an article of the present invention.
- a first article was prepared according to Example 6.
- a second article was also made using a glutaraldehyde HCl exposure of only 5 minutes. Both articles were steam sterilized and examined using FTIR.
- the article made according to Example 6 revealed a broad peak at about 1690 cm 1 and a sharp peak at about 1590 cm 1 . These peaks are believed to represent excess aldehyde groups present on the first layer and its partial hydrolysis products from steam exposure.
- This example illustrates a method for detecting the presence of a second layer of PVA attached to a first layer of PVA in an article of the present invention.
- an article constructed according to Example 10 was steam sterilized and examined using FTIR. Strong peaks at about 2950 cm 1 and about 3350 cm 1 was seen under FTIR analysis. These peaks represent signals from the hydrocarbon backbone and the hydroxyl groups of the PVA, respectively, of the first and second layers. Peaks at 1590 cm 1 and 1690 cm 1 were not seen. The absence of peaks at 1590 cm 1 and 1690 cm-' indicate that substantially all of the aldehyde groups from the cross-linking agent were consumed during the attachment of the second layer to the first layer. Accordingly, the ratio of peak area at about 2950 cm 1 to the peak area at about 1590 cm 1 is indicative of the extent to which excess, unreacted, aldehyde groups are present following attachment of a second layer to a first layer in the present invention.
- This example illustrates a method for detecting the presence of a second layer comprised of poly(lysine) attached to a first layer of PVA.
- an article made according to Example 12 was steam sterilized and examined using FTIR.
- a strong peak at about 2950 cm 1 was seen under FTIR analysis. This peak represents a signal from the hydrocarbon backbone of PVA of the first layer.
- a peak at about 1590 cm 1 was not observed.
- the absence of a peak at 1590 cm 1 indicates that substantially all of the aldehyde groups of the cross-linking agent of the first layer were consumed during the attachment of the second layer to the first layer.
- a peak at about 1650 cm 1 was observed.
- This peak represents a signal from the amide groups of the poly(lysine) moieties of the second layer.
- the ratio of peak area at about 2950 cm 1 to the peak area at about 1590 cm 1 is indicative of the extent to which excess, unreacted, aldehyde groups are present following attachment of a second layer to a first layer in the present invention.
- This example illustrates the immobilization of lysine to a second layer comprised of PVA such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% trifluoroacetic acid dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of PVA such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer according to Example 10 is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous dimethylformamide for 60 minutes. The construction is rinsed in dimethylformamide. N- ⁇ - Boc-L-lysine (Bachem California, Torrance CA) is dissolved in dimethylformamide at a concentration of 1 Omg/ml. The construction is immersed in this solution for 24 hr at 4°C with gentle agitation. The construction is then rinsed in dimethylformamide.
- the sample is immersed in a solution of 10% trifluoroacetic acid dissolved in dimethylformamide for 60 min., followed by successive rinsing in dimethyl formamide, deionized water, and phosphate buffered saline.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of
- a construction of the present invention having a second layer according to Example 10 is immersed in a 5% solution of carbonyl diimidazole dissolved in anhydrous acetone for 60 minutes. The construction is successively rinsed in acetone, then aqueous buffer (150mM NaHCO 3 , 500mM NaCl, pH 8.0, 4 * C).
- N- ⁇ -FMOC-L-lysine (Bachem California, Torrance CA) is dissolved in the coupling buffer at a concentration of 1 Omg/ml.
- the construct is immersed in this solution for 24 hr. at 4°C with gentle agitation.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% piperidine dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of PVA such that the lysine molecules are immobilized through the ⁇ -amine group oflhe molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on FMOC protection of the ⁇ -amine group of the lysine molecules.
- This example illustrates the immobilization of lysine to a second layer comprised of poly(ethyleneimine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer comprised of poly(ethyleneimine) is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous acetone for 60 minutes.
- the construction is successively rinsed in acetone, then aqueous buffer (150mM NaHCO , 500mM NaCl, pH 8.0, 4'C).
- aqueous buffer 150mM NaHCO , 500mM NaCl, pH 8.0, 4'C.
- the construct is dissolved in the coupling buffer at a concentration of 1 Omg/ml.
- the construct is immersed in this solution for 24 hr. at 4°C with gentle agitation.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% trifluoroacetic acid dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(ethyleneimine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer comprised of poly(ethyleneimine) is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous dimethylformamide for 60 minutes. The construction is rinsed in dimethylformamide.
- N- ⁇ -Boc-L-lysine (Bachem California, Torrance CA) is dissolved in dimethylformamide at a concentration of 1 Omg/ml. The construction is immersed in this solution for 24 hr at 4°C with gentle agitation. The construction is then rinsed in dimethylformamide.
- the sample is immersed in a solution of 10% trifluoroacetic acid dissolved in dimethylformamide for 60 min., followed by successive rinsing in dimethylformamide, deionized water, and phosphate buffered saline.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(ethyleneimine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on FMOC protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer comprised of poly(ethyleneimine) is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous acetone for 60 minutes.
- the construction is successively rinsed in acetone, then aqueous buffer (150mM NaHCO 3 , 500mM NaCl, pH 8.0, 4°C).
- aqueous buffer 150mM NaHCO 3 , 500mM NaCl, pH 8.0, 4°C.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% piperidine dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(ethyleneimine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on FMOC protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer comprised of poly(ethyleneimine) is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous dimethylformamide for 60 minutes. The construction is rinsed in dimethylfomiamide. N- ⁇ -FMOC-L-lysine (Bachem California, Torrance CA) is dissolved in dimethylformamide at a concentration of 1 Omg/ml. The construction is immersed in this solution for 24 hr at 4°C with gentle agitation. The construction is then rinsed in dimethylformamide.
- the sample is immersed in a solution of 10% trifluoroacetic acid dissolved in dimethylformamide for 60 min., followed by successive rinsing in dimethylformamide, deionized water, and phosphate buffered saline.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates the immobilization of lysine to a second layer comprised of poly (1-ly sine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% trifluoroacetic acid dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(l-lysine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on Boc protection of the ⁇ -amine group of the lysine molecules.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(l-lysine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on FMOC protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer according to Example 12 is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous acetone for 60 minutes.
- the construction is successively rinsed in acetone, then aqueous buffer (150mM NaHCO 3 , 500mM NaCl, pH 8.0, 'C).
- N- ⁇ -FMOC-L-lysine (Bachem California, Torrance CA) is dissolved in the coupling buffer at a concentration of 1 Omg/ml.
- the construct is immersed in this solution for 24 hr. at 4°C with gentle agitation.
- the construction is rinsed successively in coupling buffer, deionized water, and tetrahydrofuran.
- the construction is then immersed in a solution of 10% piperidine dissolved in tetrahydrofuran for 60 min. This is followed by successive rinsing in tetrahydrofuran, deionized water, and coupling buffer.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- This example illustrates another immobilization of lysine to a second layer comprised of poly(l-lysine) such that the lysine molecules are immobilized through the ⁇ -amine group of the molecule, while leaving the ⁇ -amine group of the lysine molecules are unreacted.
- This method relies on FMOC protection of the ⁇ -amine group of the lysine molecules.
- a construction of the present invention having a second layer according to Example 12 is immersed in a 5% solution of carbonyldiimidazole dissolved in anhydrous dimethylfomiamide for 60 minutes. The construction is rinsed in dimethylformamide. N- ⁇ - FMOC-L-lysine (Bachem California, Torrance CA) is dissolved in dimethylfomiamide at a concentration of 1 Omg/ml. The construction is immersed in this solution for 24 hr at 4°C with gentle agitation. The construction is then rinsed in dimethylformamide.
- the sample is immersed in a solution of 10% trifluoroacetic acid dissolved in dimethylformamide for 60 min., followed by successive rinsing in dimethylformamide, deionized water, and phosphate buffered saline.
- the resulting article contains lysine immobilized to the second layer exclusively via the ⁇ -amine terminus with the ⁇ -amine group of the lysine unreacted, or free.
- FIG. 1 This example illustrates a vascular graft made with materials of the present invention.
- a vascular graft comprised of a porous polytetrafluoroethylene material (W.L. Gore & Associates, Inc., Flagstaff, AZ) is obtained and subjected to the processes described in Examples 1 and 9, above, in order to prepare the graft for immobilization of lysine thereto.
- Lysine is attached to the second layer via any of the processes described in Examples 46-57, above.
- the resulting vascular graft has lysine immobilized thereto such that circulating plasminogen can attach to the immobilized lysine and form a thrombolytic blood contact surface thereon once the graft is implanted in a recipient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97927968A EP0910584B1 (en) | 1996-06-03 | 1997-06-02 | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
AU32297/97A AU3229797A (en) | 1996-06-03 | 1997-06-02 | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
DE1997605841 DE69705841T2 (en) | 1996-06-03 | 1997-06-02 | MATERIALS AND METHOD FOR IMMOBILIZING BIOACTIVE SPECIES ON POLYMERIC DOCKS |
CA002256766A CA2256766C (en) | 1996-06-03 | 1997-06-02 | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/660,698 | 1996-06-03 | ||
US08/660,698 US5914182A (en) | 1996-06-03 | 1996-06-03 | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
US08/863,263 | 1997-05-27 | ||
US08/863,263 US5874165A (en) | 1996-06-03 | 1997-05-27 | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997046590A1 true WO1997046590A1 (en) | 1997-12-11 |
Family
ID=27098155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/009634 WO1997046590A1 (en) | 1996-06-03 | 1997-06-02 | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
Country Status (6)
Country | Link |
---|---|
US (1) | US5874165A (en) |
EP (1) | EP0910584B1 (en) |
AU (1) | AU3229797A (en) |
CA (1) | CA2256766C (en) |
DE (1) | DE69705841T2 (en) |
WO (1) | WO1997046590A1 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859051A1 (en) * | 1997-02-14 | 1998-08-19 | Nippon Shokubai Co., Ltd. | Immobilized biocatalyst |
WO1999001167A1 (en) * | 1997-07-01 | 1999-01-14 | Minnesota Mining And Manufacturing Company | Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine |
WO1999007654A1 (en) * | 1997-08-07 | 1999-02-18 | Ben Gurion University Of The Negev Research And Development Authority | Encapsulated fertilizers |
EP0945513A2 (en) * | 1998-02-13 | 1999-09-29 | Nippon Shokubai Co., Ltd. | Method for producing L-aspartic acid |
WO1999049907A1 (en) * | 1998-03-31 | 1999-10-07 | Ppl Therapeutics (Scotland) Ltd. | Medical devices treated to discourage blood coagulation |
WO1999063101A2 (en) * | 1998-06-02 | 1999-12-09 | University Of Washington | Transfected cells and methods for treating diabetes |
US6004943A (en) * | 1995-11-27 | 1999-12-21 | Inst. Of Biomedical Engineering, Chinese Acdmy Of Med. Science | Protein-coated medical substrates for local delivery of genes and method of forming coatings on the substrates |
EP0992283A2 (en) * | 1998-09-21 | 2000-04-12 | Polymer Group, Inc. | Method and product for selectively removing ions from aqueous solutions |
EP1001267A2 (en) * | 1998-11-10 | 2000-05-17 | Nisshinbo Industries, Inc. | Carrier for immobilizing biologically active substance |
WO2000027444A1 (en) * | 1998-11-09 | 2000-05-18 | Ecole Polytechnique Federale De Lausanne | Functionalised polymers for tissue engineering |
WO2000040278A1 (en) * | 1998-12-31 | 2000-07-13 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
WO2000048642A2 (en) * | 1999-02-17 | 2000-08-24 | Surfarc Aps | Biocompatible material with a novel functionality |
WO2001090203A1 (en) * | 2000-05-25 | 2001-11-29 | Institut Francais De Recherche Pour L'exploitation De Mer (Ifremer) | Insoluble random copolymers having a specific affinity for a given protist, uses thereof and method for selecting them |
FR2823675A1 (en) * | 2001-04-19 | 2002-10-25 | Inst Nat Sante Rech Med | Biomaterial, useful in local therapy or tissue reconstruction, comprises core covered with alternate layers of polyelectrolytes of opposite charge including fixed active agent |
EP1316323A1 (en) * | 1998-12-31 | 2003-06-04 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
EP1587546A2 (en) * | 2002-12-31 | 2005-10-26 | Medtronic MiniMed, Inc. | Hydrophilic cross-linking agents for use in enzymatic sensors |
US8871236B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8871883B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible coating for implantable medical devices |
US8961588B2 (en) | 2002-03-27 | 2015-02-24 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
US9101697B2 (en) | 2004-04-30 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Hyaluronic acid based copolymers |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
USRE45744E1 (en) | 2003-12-01 | 2015-10-13 | Abbott Cardiovascular Systems Inc. | Temperature controlled crimping |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
US9339592B2 (en) | 2004-12-22 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US10259922B2 (en) | 2013-11-06 | 2019-04-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modifying a hydrophobic polymer surface and devices thereof |
US10350328B2 (en) | 2013-06-19 | 2019-07-16 | National University Of Singapore | Surface modification of medical or veterinary devices |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7266725B2 (en) * | 2001-09-03 | 2007-09-04 | Pact Xpp Technologies Ag | Method for debugging reconfigurable architectures |
US6240616B1 (en) * | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US10028851B2 (en) * | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
US8172897B2 (en) * | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
JPH10327850A (en) * | 1997-05-29 | 1998-12-15 | Res Dev Corp Of Japan | Microelement/inorganic nutrient salt diffusion-type carrier for microbial cell culture |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US6841392B2 (en) | 1998-12-22 | 2005-01-11 | Toxin Alert, Inc. | Method and apparatus for selective biological material detection |
AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7682647B2 (en) | 1999-09-03 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of a drug eluting implantable medical device |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US7220276B1 (en) * | 2000-03-06 | 2007-05-22 | Surmodics, Inc. | Endovascular graft coatings |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US8109994B2 (en) * | 2003-01-10 | 2012-02-07 | Abbott Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US7875283B2 (en) * | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
US7682648B1 (en) | 2000-05-31 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for forming polymeric coatings on stents |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7807210B1 (en) | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
JP2004537032A (en) * | 2001-02-16 | 2004-12-09 | ペプスキャン システムズ ベー.フェー. | Pixel array |
SK287686B6 (en) * | 2001-04-10 | 2011-06-06 | Ciba Specialty Chemicals Holding Inc. | Stabilized medium and high voltage cable insulation composition and a method for the production thereof |
US6712845B2 (en) | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US7682669B1 (en) | 2001-07-30 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US7989018B2 (en) * | 2001-09-17 | 2011-08-02 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US7285304B1 (en) * | 2003-06-25 | 2007-10-23 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US6863683B2 (en) | 2001-09-19 | 2005-03-08 | Abbott Laboratoris Vascular Entities Limited | Cold-molding process for loading a stent onto a stent delivery system |
US20030073961A1 (en) * | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
US20030113812A1 (en) * | 2001-10-02 | 2003-06-19 | Hemperly John J. | Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
CA2466578A1 (en) * | 2001-11-15 | 2003-05-30 | Becton, Dickinson And Company | Methods and devices for the integrated discovery of cell culture environments |
EP1463578B1 (en) * | 2002-01-09 | 2011-09-28 | Hydranautics | Method for cleaning a filtration membrane module with hollow fiber membranes |
WO2003076092A1 (en) * | 2002-03-04 | 2003-09-18 | Westinghouse Savannah River Company, Llc | In situ microbial stabilization of metals using phosphate amended bioventing/biosparging |
US7919075B1 (en) | 2002-03-20 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices |
ITMI20020729A1 (en) * | 2002-04-08 | 2003-10-08 | Resindion S R L | SUPPORTS FOR THE COVALENT IMMOBILIZATION OF ENZYMES |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US7033602B1 (en) * | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US7794743B2 (en) * | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US7396539B1 (en) * | 2002-06-21 | 2008-07-08 | Advanced Cardiovascular Systems, Inc. | Stent coatings with engineered drug release rate |
US20040063805A1 (en) * | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US20060271168A1 (en) * | 2002-10-30 | 2006-11-30 | Klaus Kleine | Degradable medical device |
US7074276B1 (en) | 2002-12-12 | 2006-07-11 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US7094256B1 (en) * | 2002-12-16 | 2006-08-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical device containing polycationic peptides |
US20060002968A1 (en) | 2004-06-30 | 2006-01-05 | Gordon Stewart | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US8435550B2 (en) * | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US7758881B2 (en) * | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20040191815A1 (en) * | 2003-01-15 | 2004-09-30 | Motoki Kyo | Array having oligonucleotides on a metal substrate |
US20040220656A1 (en) * | 2003-04-30 | 2004-11-04 | Epstein Samuel J. | Coated medical devices and methods of making the same |
US20080215137A1 (en) * | 2003-04-30 | 2008-09-04 | Boston Scientific Scimed, Inc. | Therapeutic driving layer for a medical device |
US8791171B2 (en) * | 2003-05-01 | 2014-07-29 | Abbott Cardiovascular Systems Inc. | Biodegradable coatings for implantable medical devices |
DE10323597A1 (en) * | 2003-05-19 | 2004-12-09 | Aesculap Ag & Co. Kg | Medical device, process for its manufacture and use |
US7186789B2 (en) * | 2003-06-11 | 2007-03-06 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings |
US7431959B1 (en) | 2003-07-31 | 2008-10-07 | Advanced Cardiovascular Systems Inc. | Method and system for irradiation of a drug eluting implantable medical device |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
US7645474B1 (en) | 2003-07-31 | 2010-01-12 | Advanced Cardiovascular Systems, Inc. | Method and system of purifying polymers for use with implantable medical devices |
CA2539151A1 (en) * | 2003-09-15 | 2005-03-31 | Eric Wickstrom | Implants with attached silylated therapeutic agents |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US7704544B2 (en) | 2003-10-07 | 2010-04-27 | Advanced Cardiovascular Systems, Inc. | System and method for coating a tubular implantable medical device |
US7329413B1 (en) | 2003-11-06 | 2008-02-12 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof |
US8192752B2 (en) | 2003-11-21 | 2012-06-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US7560492B1 (en) | 2003-11-25 | 2009-07-14 | Advanced Cardiovascular Systems, Inc. | Polysulfone block copolymers as drug-eluting coating material |
US7807722B2 (en) | 2003-11-26 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Biobeneficial coating compositions and methods of making and using thereof |
US7435788B2 (en) | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US8309112B2 (en) | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US8685431B2 (en) | 2004-03-16 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
US20050214339A1 (en) * | 2004-03-29 | 2005-09-29 | Yiwen Tang | Biologically degradable compositions for medical applications |
US8778014B1 (en) | 2004-03-31 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Coatings for preventing balloon damage to polymer coated stents |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US8568469B1 (en) | 2004-06-28 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Stent locking element and a method of securing a stent on a delivery system |
US8241554B1 (en) | 2004-06-29 | 2012-08-14 | Advanced Cardiovascular Systems, Inc. | Method of forming a stent pattern on a tube |
US20050287184A1 (en) | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US7731890B2 (en) * | 2006-06-15 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Methods of fabricating stents with enhanced fracture toughness |
US7971333B2 (en) * | 2006-05-30 | 2011-07-05 | Advanced Cardiovascular Systems, Inc. | Manufacturing process for polymetric stents |
US8747879B2 (en) * | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device to reduce chance of late inflammatory response |
US20060020330A1 (en) * | 2004-07-26 | 2006-01-26 | Bin Huang | Method of fabricating an implantable medical device with biaxially oriented polymers |
US8747878B2 (en) | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device by controlling crystalline structure |
US8778256B1 (en) | 2004-09-30 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Deformation of a polymer tube in the fabrication of a medical article |
US8357391B2 (en) | 2004-07-30 | 2013-01-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
US20060041102A1 (en) * | 2004-08-23 | 2006-02-23 | Advanced Cardiovascular Systems, Inc. | Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same |
US9283099B2 (en) * | 2004-08-25 | 2016-03-15 | Advanced Cardiovascular Systems, Inc. | Stent-catheter assembly with a releasable connection for stent retention |
US7648727B2 (en) | 2004-08-26 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Methods for manufacturing a coated stent-balloon assembly |
US7244443B2 (en) * | 2004-08-31 | 2007-07-17 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US7229471B2 (en) * | 2004-09-10 | 2007-06-12 | Advanced Cardiovascular Systems, Inc. | Compositions containing fast-leaching plasticizers for improved performance of medical devices |
US8110211B2 (en) | 2004-09-22 | 2012-02-07 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US7875233B2 (en) | 2004-09-30 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a biaxially oriented implantable medical device |
US8173062B1 (en) | 2004-09-30 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube in fabricating a medical article |
US8043553B1 (en) | 2004-09-30 | 2011-10-25 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article |
US7390497B2 (en) | 2004-10-29 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US8609123B2 (en) | 2004-11-29 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Derivatized poly(ester amide) as a biobeneficial coating |
US7892592B1 (en) | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
DE502004005666D1 (en) * | 2004-12-23 | 2008-01-17 | Micronas Holding Gmbh | Method for producing a sensor chip and sensor chip blank |
US7419504B2 (en) | 2004-12-27 | 2008-09-02 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) block copolymers |
US8007775B2 (en) | 2004-12-30 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US20060224226A1 (en) * | 2005-03-31 | 2006-10-05 | Bin Huang | In-vivo radial orientation of a polymeric implantable medical device |
US7381048B2 (en) * | 2005-04-12 | 2008-06-03 | Advanced Cardiovascular Systems, Inc. | Stents with profiles for gripping a balloon catheter and molds for fabricating stents |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
US8778375B2 (en) | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US7637941B1 (en) | 2005-05-11 | 2009-12-29 | Advanced Cardiovascular Systems, Inc. | Endothelial cell binding coatings for rapid encapsulation of bioerodable stents |
US8685680B2 (en) * | 2005-05-13 | 2014-04-01 | Thomas P. Binder | Method for producing fats or oils |
US7291166B2 (en) * | 2005-05-18 | 2007-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
US7622070B2 (en) * | 2005-06-20 | 2009-11-24 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing an implantable polymeric medical device |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US8021676B2 (en) | 2005-07-08 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Functionalized chemically inert polymers for coatings |
US7785647B2 (en) | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
CN100335141C (en) * | 2005-07-26 | 2007-09-05 | 北京科技大学 | Method for preparing bionic multi-layered structure cartilage implant material |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
US7658880B2 (en) * | 2005-07-29 | 2010-02-09 | Advanced Cardiovascular Systems, Inc. | Polymeric stent polishing method and apparatus |
US7297758B2 (en) * | 2005-08-02 | 2007-11-20 | Advanced Cardiovascular Systems, Inc. | Method for extending shelf-life of constructs of semi-crystallizable polymers |
US20070038290A1 (en) * | 2005-08-15 | 2007-02-15 | Bin Huang | Fiber reinforced composite stents |
US7476245B2 (en) * | 2005-08-16 | 2009-01-13 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
US20070045252A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with a process gas |
US20070045255A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with an optimized process gas |
US9248034B2 (en) * | 2005-08-23 | 2016-02-02 | Advanced Cardiovascular Systems, Inc. | Controlled disintegrating implantable medical devices |
US20100077529A1 (en) * | 2005-09-30 | 2010-04-01 | General Electric Company | Article, laminate and associated methods |
US20090205116A1 (en) * | 2005-09-30 | 2009-08-20 | General Electric Company | Article, laminate and associated methods |
US7381331B2 (en) * | 2005-09-30 | 2008-06-03 | General Electric Company | Hydrophilic membrane and associated method |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070151961A1 (en) * | 2006-01-03 | 2007-07-05 | Klaus Kleine | Fabrication of an implantable medical device with a modified laser beam |
US20070156230A1 (en) | 2006-01-04 | 2007-07-05 | Dugan Stephen R | Stents with radiopaque markers |
US7951185B1 (en) | 2006-01-06 | 2011-05-31 | Advanced Cardiovascular Systems, Inc. | Delivery of a stent at an elevated temperature |
JP5530633B2 (en) * | 2006-01-06 | 2014-06-25 | イー・エム・デイー・ミリポア・コーポレイシヨン | Affinity chromatography matrix and its production and use. |
US20070179219A1 (en) * | 2006-01-31 | 2007-08-02 | Bin Huang | Method of fabricating an implantable medical device using gel extrusion and charge induced orientation |
US20070196428A1 (en) | 2006-02-17 | 2007-08-23 | Thierry Glauser | Nitric oxide generating medical devices |
US7713637B2 (en) | 2006-03-03 | 2010-05-11 | Advanced Cardiovascular Systems, Inc. | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US7964210B2 (en) * | 2006-03-31 | 2011-06-21 | Abbott Cardiovascular Systems Inc. | Degradable polymeric implantable medical devices with a continuous phase and discrete phase |
US20070254012A1 (en) * | 2006-04-28 | 2007-11-01 | Ludwig Florian N | Controlled degradation and drug release in stents |
US8304012B2 (en) | 2006-05-04 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Method for drying a stent |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US7761968B2 (en) * | 2006-05-25 | 2010-07-27 | Advanced Cardiovascular Systems, Inc. | Method of crimping a polymeric stent |
US8752268B2 (en) | 2006-05-26 | 2014-06-17 | Abbott Cardiovascular Systems Inc. | Method of making stents with radiopaque markers |
US7775178B2 (en) | 2006-05-26 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus and method |
US7951194B2 (en) | 2006-05-26 | 2011-05-31 | Abbott Cardiovascular Sysetms Inc. | Bioabsorbable stent with radiopaque coating |
US7842737B2 (en) | 2006-09-29 | 2010-11-30 | Abbott Cardiovascular Systems Inc. | Polymer blend-bioceramic composite implantable medical devices |
US7959940B2 (en) * | 2006-05-30 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical devices |
US8343530B2 (en) * | 2006-05-30 | 2013-01-01 | Abbott Cardiovascular Systems Inc. | Polymer-and polymer blend-bioceramic composite implantable medical devices |
US20070282434A1 (en) * | 2006-05-30 | 2007-12-06 | Yunbing Wang | Copolymer-bioceramic composite implantable medical devices |
US20080058916A1 (en) * | 2006-05-31 | 2008-03-06 | Bin Huang | Method of fabricating polymeric self-expandable stent |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US8486135B2 (en) | 2006-06-01 | 2013-07-16 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from branched polymers |
US20070281073A1 (en) * | 2006-06-01 | 2007-12-06 | Gale David C | Enhanced adhesion of drug delivery coatings on stents |
US20070282433A1 (en) * | 2006-06-01 | 2007-12-06 | Limon Timothy A | Stent with retention protrusions formed during crimping |
US8034287B2 (en) * | 2006-06-01 | 2011-10-11 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US8323676B2 (en) * | 2008-06-30 | 2012-12-04 | Abbott Cardiovascular Systems Inc. | Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug |
US20090258028A1 (en) * | 2006-06-05 | 2009-10-15 | Abbott Cardiovascular Systems Inc. | Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug |
US8703167B2 (en) * | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
US20070286941A1 (en) * | 2006-06-13 | 2007-12-13 | Bin Huang | Surface treatment of a polymeric stent |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8114150B2 (en) * | 2006-06-14 | 2012-02-14 | Advanced Cardiovascular Systems, Inc. | RGD peptide attached to bioabsorbable stents |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8535372B1 (en) | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
US8333000B2 (en) | 2006-06-19 | 2012-12-18 | Advanced Cardiovascular Systems, Inc. | Methods for improving stent retention on a balloon catheter |
US20070290412A1 (en) * | 2006-06-19 | 2007-12-20 | John Capek | Fabricating a stent with selected properties in the radial and axial directions |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US9072820B2 (en) * | 2006-06-26 | 2015-07-07 | Advanced Cardiovascular Systems, Inc. | Polymer composite stent with polymer particles |
US20070299511A1 (en) * | 2006-06-27 | 2007-12-27 | Gale David C | Thin stent coating |
US8128688B2 (en) * | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US7794776B1 (en) | 2006-06-29 | 2010-09-14 | Abbott Cardiovascular Systems Inc. | Modification of polymer stents with radiation |
US7740791B2 (en) * | 2006-06-30 | 2010-06-22 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a stent with features by blow molding |
US20080009938A1 (en) * | 2006-07-07 | 2008-01-10 | Bin Huang | Stent with a radiopaque marker and method for making the same |
US7823263B2 (en) | 2006-07-11 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Method of removing stent islands from a stent |
US20080014244A1 (en) * | 2006-07-13 | 2008-01-17 | Gale David C | Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers |
US7998404B2 (en) * | 2006-07-13 | 2011-08-16 | Advanced Cardiovascular Systems, Inc. | Reduced temperature sterilization of stents |
US7757543B2 (en) | 2006-07-13 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US7886419B2 (en) * | 2006-07-18 | 2011-02-15 | Advanced Cardiovascular Systems, Inc. | Stent crimping apparatus and method |
US8016879B2 (en) * | 2006-08-01 | 2011-09-13 | Abbott Cardiovascular Systems Inc. | Drug delivery after biodegradation of the stent scaffolding |
US20080091262A1 (en) * | 2006-10-17 | 2008-04-17 | Gale David C | Drug delivery after biodegradation of the stent scaffolding |
US8703169B1 (en) | 2006-08-15 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating comprising carrageenan and a biostable polymer |
US9173733B1 (en) | 2006-08-21 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Tracheobronchial implantable medical device and methods of use |
US7923022B2 (en) * | 2006-09-13 | 2011-04-12 | Advanced Cardiovascular Systems, Inc. | Degradable polymeric implantable medical devices with continuous phase and discrete phase |
US8099849B2 (en) | 2006-12-13 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Optimizing fracture toughness of polymeric stent |
US8597673B2 (en) | 2006-12-13 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Coating of fast absorption or dissolution |
US20080243228A1 (en) * | 2007-03-28 | 2008-10-02 | Yunbing Wang | Implantable medical devices fabricated from block copolymers |
US8262723B2 (en) | 2007-04-09 | 2012-09-11 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from polymer blends with star-block copolymers |
US8147769B1 (en) | 2007-05-16 | 2012-04-03 | Abbott Cardiovascular Systems Inc. | Stent and delivery system with reduced chemical degradation |
US7829008B2 (en) * | 2007-05-30 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Fabricating a stent from a blow molded tube |
US7959857B2 (en) * | 2007-06-01 | 2011-06-14 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US8293260B2 (en) * | 2007-06-05 | 2012-10-23 | Abbott Cardiovascular Systems Inc. | Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices |
US20080306582A1 (en) * | 2007-06-05 | 2008-12-11 | Yunbing Wang | Implantable medical devices with elastomeric copolymer coatings |
US8202528B2 (en) * | 2007-06-05 | 2012-06-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices with elastomeric block copolymer coatings |
US8425591B1 (en) | 2007-06-11 | 2013-04-23 | Abbott Cardiovascular Systems Inc. | Methods of forming polymer-bioceramic composite medical devices with bioceramic particles |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US7901452B2 (en) * | 2007-06-27 | 2011-03-08 | Abbott Cardiovascular Systems Inc. | Method to fabricate a stent having selected morphology to reduce restenosis |
US7955381B1 (en) | 2007-06-29 | 2011-06-07 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical device with different types of bioceramic particles |
SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
US20090191399A1 (en) * | 2008-01-25 | 2009-07-30 | General Electric Company | Permanent hydrophilic porous coatings onto a substrate and porous membranes thereof |
US10092881B2 (en) * | 2008-01-25 | 2018-10-09 | Bha Altair, Llc | Permanent hydrophilic porous coatings and methods of making them |
US20090191398A1 (en) * | 2008-01-25 | 2009-07-30 | General Electric Company | Membranes comprising hydrophilic coatings |
IL192262A (en) | 2008-06-17 | 2016-05-31 | Z H T Eng Equipment And Tech Ltd | Polymer adapted to release bioactive agents in vivo, pharmaceutical composition comprising it and method of preparation thereof |
US8765162B2 (en) * | 2008-06-30 | 2014-07-01 | Abbott Cardiovascular Systems Inc. | Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same |
US20120135658A1 (en) * | 2008-09-30 | 2012-05-31 | General Electric Company | Protective article and methods of manufacture thereof |
US8996134B2 (en) | 2008-11-07 | 2015-03-31 | W. L. Gore & Associates, Inc. | Implantable lead |
US8364281B2 (en) * | 2008-11-07 | 2013-01-29 | W. L. Gore & Associates, Inc. | Implantable lead |
US8257640B2 (en) * | 2009-08-07 | 2012-09-04 | Zeus Industrial Products, Inc. | Multilayered composite structure with electrospun layer |
US20130268062A1 (en) | 2012-04-05 | 2013-10-10 | Zeus Industrial Products, Inc. | Composite prosthetic devices |
US8658707B2 (en) | 2009-03-24 | 2014-02-25 | W. L. Gore & Associates, Inc. | Expandable functional TFE copolymer fine powder, the expanded functional products obtained therefrom and reaction of the expanded products |
US9139669B2 (en) | 2009-03-24 | 2015-09-22 | W. L. Gore & Associates, Inc. | Expandable functional TFE copolymer fine powder, the expandable functional products obtained therefrom and reaction of the expanded products |
US8568471B2 (en) | 2010-01-30 | 2013-10-29 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
US8808353B2 (en) | 2010-01-30 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds having a low crossing profile |
US8657138B2 (en) | 2010-06-24 | 2014-02-25 | Sussex Im, Inc. | Container having a pre-curved lid |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US20120310210A1 (en) | 2011-03-04 | 2012-12-06 | Campbell Carey V | Eluting medical devices |
EP2734537B1 (en) | 2011-07-20 | 2022-12-21 | Zepteon, Incorporated | Polypeptide separation methods |
US8726483B2 (en) | 2011-07-29 | 2014-05-20 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
US20130035665A1 (en) | 2011-08-05 | 2013-02-07 | W. L. Gore & Associates, Inc. | Polymer-Based Occlusion Devices, Systems and Methods |
DE102012101240A1 (en) | 2012-02-16 | 2013-08-22 | Technische Universität Ilmenau | Method for determining settling of biological cells e.g. human cells, on carrier e.g. foil, involves applying biological cells on chemically modified areas of carrier, and determining adhesion of cells on chemically modified areas |
EP2669009A1 (en) * | 2012-05-31 | 2013-12-04 | Studiengesellschaft Kohle mbH | Process for the immobilization of catalysts on textile materials, the obtained textile materials and the use of said materials |
US9890191B2 (en) | 2012-09-03 | 2018-02-13 | Kaneka Corporation | Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules |
EP2839949B1 (en) | 2013-08-23 | 2016-10-12 | W.L. Gore & Associates GmbH | Process for the production of a structured film |
JPWO2015041218A1 (en) | 2013-09-17 | 2017-03-02 | 株式会社カネカ | Novel antibody purification method and antibody obtained therefrom (Novel Antibody Purification Method), and novel antibody purification method using cation exchange group and novel antibody purification antibody method |
US9862859B2 (en) | 2014-09-12 | 2018-01-09 | W. L. Gore & Associates, Inc. | Porous air permeable polytetrafluoroethylene composites with improved mechanical and thermal properties |
US20160075914A1 (en) | 2014-09-12 | 2016-03-17 | W. L. Gore & Associates, Inc. | Porous Air Permeable Polytetrafluoroethylene Composites with Improved Mechanical and Thermal Properties |
US9999527B2 (en) | 2015-02-11 | 2018-06-19 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
US9700443B2 (en) | 2015-06-12 | 2017-07-11 | Abbott Cardiovascular Systems Inc. | Methods for attaching a radiopaque marker to a scaffold |
CN105597681B (en) * | 2016-03-07 | 2017-11-14 | 北京林业大学 | A kind of preparation method for the NCC/PVA/PVP carbon blended sponges that can efficiently remove Heavy Metals in Waters ion and organic dyestuff |
US20210147790A1 (en) * | 2019-11-06 | 2021-05-20 | General Automation Lab Technologies Inc. | Method for picking biological sample |
CN114949374B (en) * | 2022-05-24 | 2023-06-13 | 安徽大学 | Antibacterial bone-promoting difunctional titanium metal orthopedic implant and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011297A1 (en) * | 1989-03-20 | 1990-10-04 | La Jolla Cancer Research Foundation | Hydrophobic attachment site for adhesion peptides |
WO1991005036A2 (en) * | 1989-09-28 | 1991-04-18 | Board Of Regents, The University Of Texas System | Surfaces having desirable cell adhesive effects |
WO1995013858A1 (en) * | 1993-11-15 | 1995-05-26 | W.L. Gore & Associates, Inc. | Hydrophilic compositions with increased thermal and solvent resistance |
WO1995025547A1 (en) * | 1994-03-24 | 1995-09-28 | University Of Washington | Devices and methods for implanting transduced cells |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1538810A (en) * | 1976-08-10 | 1979-01-24 | Sumitomo Electric Industries | Hydrophilic porous fluorocarbon structures and process for their production |
US4193138A (en) * | 1976-08-20 | 1980-03-18 | Sumitomo Electric Industries, Ltd. | Composite structure vascular prostheses |
US5217492A (en) * | 1982-09-29 | 1993-06-08 | Bio-Metric Systems, Inc. | Biomolecule attachment to hydrophobic surfaces |
JPS5968344A (en) * | 1982-10-12 | 1984-04-18 | Agency Of Ind Science & Technol | Unsymmetrical functional membrane and production thereof |
GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
JPS61151245A (en) * | 1984-12-25 | 1986-07-09 | Sumitomo Electric Ind Ltd | Method for treating surface of porous thin membrane material |
US5263992A (en) * | 1986-10-17 | 1993-11-23 | Bio-Metric Systems, Inc. | Biocompatible device with covalently bonded biocompatible agent |
US4885250A (en) * | 1987-03-02 | 1989-12-05 | E. I. Du Pont De Nemours And Company | Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports |
US5006624A (en) * | 1987-05-14 | 1991-04-09 | The Dow Chemical Company | Fluorocarbon containing, reactive polymeric surfactants and coating compositions therefrom |
US4929666A (en) * | 1987-05-14 | 1990-05-29 | The Dow Chemical Company | Fluorocarbon containing, reactive polymeric surfactants and coating compositions therefrom |
DE3850957T2 (en) * | 1987-09-17 | 1995-03-30 | Commw Scient Ind Res Org | NEUTRALIZED PERFLUORO-3,6-DIOXA-4-METHYL-7-OCT SULPHONYL FLUORIDE COPOLYMER AREA FOR FIXING AND BREEDING ANIMAL CELLS. |
JPH0286822A (en) * | 1988-05-02 | 1990-03-27 | Terumo Corp | Hydrophilic porous membrane, production thereof and liquid filter using the same membrane |
WO1989011500A1 (en) * | 1988-05-17 | 1989-11-30 | Commonwealth Scientific And Industrial Research Or | Hydrophilic non-swelling multilayer polymeric materials and process for their manufacture |
US5183545A (en) * | 1989-04-28 | 1993-02-02 | Branca Phillip A | Electrolytic cell with composite, porous diaphragm |
US5240747A (en) * | 1989-05-11 | 1993-08-31 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for modifying surfaces of materials |
EP0397130B1 (en) * | 1989-05-11 | 1995-04-19 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Medical device having highly biocompatible surface and method for manufacturing the same |
EP0402718B1 (en) * | 1989-06-03 | 1994-11-02 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Control of cell arrangement |
US5278063A (en) * | 1989-09-28 | 1994-01-11 | Board Of Regents The University Of Texas System | Chemical modification of promote animal cell adhesion on surfaces |
US5213898A (en) * | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5049403A (en) * | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5369012A (en) * | 1992-03-26 | 1994-11-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals |
WO1992007899A2 (en) * | 1990-10-30 | 1992-05-14 | Minnesota Mining And Manufacturing Company | Articles having a hydrophilic polymeric shell and method for preparing same |
DE69229312T2 (en) * | 1991-03-29 | 1999-11-04 | Vascular Graft Research Center | ARTIFICIAL BLOOD VESSEL FROM COMPOSITE MATERIAL |
US5462781A (en) * | 1991-06-14 | 1995-10-31 | W. L. Gore & Associates, Inc. | Surface modified porous expanded polytetrafluoroethylene and process for making |
EP0526797A1 (en) * | 1991-08-07 | 1993-02-10 | Japan Gore-Tex, Inc. | Hydrophilic fluoropolymer particles and products thereof |
EP0561507A1 (en) * | 1992-03-16 | 1993-09-22 | Mizu Systems, Inc. | Method for grafting preformed hydrophilic polymers onto hydrophobic polymer substrates |
US5512474A (en) * | 1992-05-29 | 1996-04-30 | Bsi Corporation | Cell culture support containing a cell adhesion factor and a positively-charged molecule |
US5209850A (en) * | 1992-06-19 | 1993-05-11 | W. L. Gore & Associates, Inc. | Hydrophilic membranes |
US5344455A (en) * | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
US5308641A (en) * | 1993-01-19 | 1994-05-03 | Medtronic, Inc. | Biocompatibility of solid surfaces |
JP2871435B2 (en) * | 1993-04-22 | 1999-03-17 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Method for producing a hydrophilic polymer coated perfluorocarbon polymer based matrix |
US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
US5352511A (en) * | 1993-11-15 | 1994-10-04 | W. L. Gore & Associates, Onc. | Hydrophilic compositions with increased thermal resistance |
US5505713A (en) * | 1994-04-01 | 1996-04-09 | Minimed Inc. | Indwelling catheter with stable enzyme coating |
-
1997
- 1997-05-27 US US08/863,263 patent/US5874165A/en not_active Expired - Lifetime
- 1997-06-02 DE DE1997605841 patent/DE69705841T2/en not_active Expired - Lifetime
- 1997-06-02 CA CA002256766A patent/CA2256766C/en not_active Expired - Lifetime
- 1997-06-02 EP EP97927968A patent/EP0910584B1/en not_active Expired - Lifetime
- 1997-06-02 AU AU32297/97A patent/AU3229797A/en not_active Abandoned
- 1997-06-02 WO PCT/US1997/009634 patent/WO1997046590A1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011297A1 (en) * | 1989-03-20 | 1990-10-04 | La Jolla Cancer Research Foundation | Hydrophobic attachment site for adhesion peptides |
WO1991005036A2 (en) * | 1989-09-28 | 1991-04-18 | Board Of Regents, The University Of Texas System | Surfaces having desirable cell adhesive effects |
WO1995013858A1 (en) * | 1993-11-15 | 1995-05-26 | W.L. Gore & Associates, Inc. | Hydrophilic compositions with increased thermal and solvent resistance |
WO1995025547A1 (en) * | 1994-03-24 | 1995-09-28 | University Of Washington | Devices and methods for implanting transduced cells |
Non-Patent Citations (1)
Title |
---|
KONDOH A ET AL: "TWO-DIMENSIONAL ARTIFICIAL EXTRACELLULAR MATRIX: BIOADHESIVE PEPTIDE-IMMOBILIZED SURFACE DESIGN", JOURNAL OF APPLIED POLYMER SCIENCE, vol. 47, no. 11, pages 1983 - 1988, XP000451898 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004943A (en) * | 1995-11-27 | 1999-12-21 | Inst. Of Biomedical Engineering, Chinese Acdmy Of Med. Science | Protein-coated medical substrates for local delivery of genes and method of forming coatings on the substrates |
EP0859051A1 (en) * | 1997-02-14 | 1998-08-19 | Nippon Shokubai Co., Ltd. | Immobilized biocatalyst |
US5962280A (en) * | 1997-02-14 | 1999-10-05 | Nippon Shokubai Co., Ltd. | Microorganisms immobilized on a solid support with a quaternary polyallylamine polymer |
WO1999001167A1 (en) * | 1997-07-01 | 1999-01-14 | Minnesota Mining And Manufacturing Company | Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine |
WO1999007654A1 (en) * | 1997-08-07 | 1999-02-18 | Ben Gurion University Of The Negev Research And Development Authority | Encapsulated fertilizers |
EP0945513A2 (en) * | 1998-02-13 | 1999-09-29 | Nippon Shokubai Co., Ltd. | Method for producing L-aspartic acid |
EP0945513A3 (en) * | 1998-02-13 | 2001-08-22 | Nippon Shokubai Co., Ltd. | Method for producing L-aspartic acid |
WO1999049907A1 (en) * | 1998-03-31 | 1999-10-07 | Ppl Therapeutics (Scotland) Ltd. | Medical devices treated to discourage blood coagulation |
WO1999063101A3 (en) * | 1998-06-02 | 2000-02-17 | Univ Washington | Transfected cells and methods for treating diabetes |
US7341869B2 (en) | 1998-06-02 | 2008-03-11 | The University Of Washington | Compositions and methods for treating diabetes |
AU752606B2 (en) * | 1998-06-02 | 2002-09-26 | University Of Washington | Compositions and methods for treating diabetes |
US6537806B1 (en) | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
WO1999063101A2 (en) * | 1998-06-02 | 1999-12-09 | University Of Washington | Transfected cells and methods for treating diabetes |
EP0992283A2 (en) * | 1998-09-21 | 2000-04-12 | Polymer Group, Inc. | Method and product for selectively removing ions from aqueous solutions |
EP0992283A3 (en) * | 1998-09-21 | 2000-06-14 | Polymer Group, Inc. | Method and product for selectively removing ions from aqueous solutions |
WO2000027444A1 (en) * | 1998-11-09 | 2000-05-18 | Ecole Polytechnique Federale De Lausanne | Functionalised polymers for tissue engineering |
EP1001267A2 (en) * | 1998-11-10 | 2000-05-17 | Nisshinbo Industries, Inc. | Carrier for immobilizing biologically active substance |
EP1001267A3 (en) * | 1998-11-10 | 2000-09-06 | Nisshinbo Industries, Inc. | Carrier for immobilizing biologically active substance |
AU760901B2 (en) * | 1998-12-31 | 2003-05-22 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
WO2000040278A1 (en) * | 1998-12-31 | 2000-07-13 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
CN100377749C (en) * | 1998-12-31 | 2008-04-02 | 血管技术药物公司 | Stent grafts with bioactive coatings |
EP1316323A1 (en) * | 1998-12-31 | 2003-06-04 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
KR100783299B1 (en) * | 1998-12-31 | 2007-12-10 | 안지오테크 파마슈티칼즈, 인코포레이티드 | Stent grafts with bioactive coatings |
WO2000048642A3 (en) * | 1999-02-17 | 2000-12-21 | Surfarc Aps | Biocompatible material with a novel functionality |
WO2000048642A2 (en) * | 1999-02-17 | 2000-08-24 | Surfarc Aps | Biocompatible material with a novel functionality |
WO2001090203A1 (en) * | 2000-05-25 | 2001-11-29 | Institut Francais De Recherche Pour L'exploitation De Mer (Ifremer) | Insoluble random copolymers having a specific affinity for a given protist, uses thereof and method for selecting them |
FR2809405A1 (en) * | 2000-05-25 | 2001-11-30 | Ifremer | INSOLUBLE STATISTIC COPOLYMERS HAVING SPECIFIC AFFINITY TO A GIVEN PROTIST, USES THEREOF AND METHOD OF SELECTING THEM |
FR2823675A1 (en) * | 2001-04-19 | 2002-10-25 | Inst Nat Sante Rech Med | Biomaterial, useful in local therapy or tissue reconstruction, comprises core covered with alternate layers of polyelectrolytes of opposite charge including fixed active agent |
WO2002085423A1 (en) * | 2001-04-19 | 2002-10-31 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Biomaterials with bioactive coatings |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US8961588B2 (en) | 2002-03-27 | 2015-02-24 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
US8871236B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8871883B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible coating for implantable medical devices |
US8986726B2 (en) | 2002-12-11 | 2015-03-24 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
EP1587546A2 (en) * | 2002-12-31 | 2005-10-26 | Medtronic MiniMed, Inc. | Hydrophilic cross-linking agents for use in enzymatic sensors |
EP1587546A4 (en) * | 2002-12-31 | 2007-02-14 | Medtronic Minimed Inc | Hydrophilic cross-linking agents for use in enzymatic sensors |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
USRE45744E1 (en) | 2003-12-01 | 2015-10-13 | Abbott Cardiovascular Systems Inc. | Temperature controlled crimping |
US9101697B2 (en) | 2004-04-30 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Hyaluronic acid based copolymers |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9375445B2 (en) | 2004-06-18 | 2016-06-28 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US9339592B2 (en) | 2004-12-22 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US10350328B2 (en) | 2013-06-19 | 2019-07-16 | National University Of Singapore | Surface modification of medical or veterinary devices |
US10259922B2 (en) | 2013-11-06 | 2019-04-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modifying a hydrophobic polymer surface and devices thereof |
Also Published As
Publication number | Publication date |
---|---|
AU3229797A (en) | 1998-01-05 |
EP0910584B1 (en) | 2001-07-25 |
CA2256766C (en) | 2002-11-26 |
EP0910584A1 (en) | 1999-04-28 |
DE69705841D1 (en) | 2001-08-30 |
US5874165A (en) | 1999-02-23 |
DE69705841T2 (en) | 2002-04-04 |
CA2256766A1 (en) | 1997-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0910584B1 (en) | Materials and methods for the immobilization of bioactive species onto polymeric substrates | |
US5897955A (en) | Materials and methods for the immobilization of bioactive species onto polymeric substrates | |
Kikuchi et al. | Nanostructured designs of biomedical materials: applications of cell sheet engineering to functional regenerative tissues and organs | |
EP0918550B1 (en) | Materials and methods for the immobilization of bioactive species onto biodegradable polymers | |
EP0494216B1 (en) | Surfaces having desirable cell adhesive effects | |
CA2354060C (en) | Apparatus and method for control of tissue/implant interactions | |
Elbert et al. | Surface treatments of polymers for biocompatibility | |
AU716543B2 (en) | Immobilization of chemical species in crosslinked matrices | |
US5700559A (en) | Durable hydrophilic surface coatings | |
Vladkova | Surface engineered polymeric biomaterials with improved biocontact properties | |
US20030113478A1 (en) | Surface coating method and coated device | |
CA2500410A1 (en) | Programmable scaffold and methods for making and using the same | |
Tong et al. | Protein adsorption and cell adhesion on RGD-functionalized silicon substrate surfaces | |
Kabanov | Preparation of polymeric biomaterials with the aid of radiation-chemical methods | |
KR20190052547A (en) | Substrate for cell culture and cell method for preparing cell sheet | |
JPS63196273A (en) | Substrate for cell culture | |
EP1152774A2 (en) | Biocompatible material with a novel functionality | |
Rosellini et al. | Engineering of multifunctional scaffolds for myocardial repair through nanofunctionalization and microfabrication of novel polymeric biomaterials | |
Zustiak | Tailoring Hydrogel Adhesiveness to Cells, Proteins, and Bacteria | |
JP2011092489A (en) | Implant member | |
Hubbell et al. | Compositions for coating microcapsules and other surfaces | |
JPH01305960A (en) | Substrate and vivo composite artificial organ | |
Wang | Biomimetic fluorocarbon surfactant polymers designed for use on small diameter ePTFE vascular graft | |
JPS63279785A (en) | Substrate for cell culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2256766 Country of ref document: CA Ref country code: CA Ref document number: 2256766 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997927968 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98500816 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997927968 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997927968 Country of ref document: EP |